Perspectives on Ethnic and Racial Disparities in Alzheimer's Disease and Related Dementias: Update and Areas of Immediate Need

A full list of authors and affiliations appears at the end of the article.

Abstract

Alzheimer's disease and Related Dementias (ADRD) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRD predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRD among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of Professional Interest Areas (PIAs), each focusing on a major scientific area associated with ADRD. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross-PIA white paper that provides both a concise "state-of-the-science" report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.

Introduction

Alzheimer's disease and Related Dementias (ADRD) are a global crisis facing the aging population and society as a whole. The number of people aged 65 years and older is >35 million in Japan (the world's fastest growing aging population) [1, 2], approximately 48 million in the United States (U.S.) [3], nearly 120 million in China [4] and 104 million in India (60) [5] and these numbers are expected to grow rapidly over the next several decades [2–5]. With this growth, ADRD are predicted to become the single greatest challenge facing health care and medical systems across the world [6]. This includes low income and middle income countries [7]. It is anticipated that the nearly 47 million ADRD cases globally, will increase by 10 million new cases each year [8]. Despite the fact that the global population is already ethnically and racially diverse [9–11], there remain substantial gaps in the scientific literature regarding the impact of ethnic and racial factors (herein referred to as ethnoracial) on ADRD.

⁺Address correspondence to: Sid O'Bryant, Ph.D., University of North Texas Health Science Center, Fort Worth, USA; sid.obryant@unthsc.edu; 1+817-735-2962.
*Denotes co-first authors.

The extant literature supports the need for additional research into the impact of ethnoracial factors on ADRD. Ethnoracial factors have been found to be important when considering biological (e.g., genetic, cerebrospinal fluid [CSF] and blood proteomics) [12–17] and medical risk factors for AD (e.g. hypertension, diabetes, obesity, depression) [14, 18]. These factors may be related to previously demonstrated differences in incidence, timing of diagnosis, clinical presentation and course of AD between different ethnoracial groups [14, 19, 20]. Ethnoracial factors, with regards to perceptions of the normality of cognitive changes [21, 22], insurance coverage and access to health care, [17, 19], and agreement to participate in clinical trials [17, 19, 23], are also previously documented factors for consideration. Additional factors such as differing emphasis on family and respect for elders are important considerations when seeking to enroll diverse ethnoracial groups into research studies on ADRD [17, 21, 24]. Oftentimes scientists are not trained to effectively partner with diverse communities to build trust to facilitate recruiting, communicate strategies about health research to study potential participants, and develop culturally informed retention strategies. For example, there are oftentimes few, if any, researchers or staff from underrepresented groups on the research teams [25]. Study design resources and expertise barriers include insufficient budgets for recruitment costs, limited resources to translate documents or adapt literacy levels, inability to develop relationships with minority physicians [26], limited expertise to culturally tailor and translate study documents. Participant level barriers, more often cited than those regarding scientists and study design, reflect a myriad of concerns such as mistrust, and limited knowledge about clinical research that affect both recruitment and retention [27]. These factors are relevant to each topic area covered below. In the U.S., the 2012 National Alzheimer's Project Act specifically calls for increased enrollment of diverse ethnoracial populations into ADRD research studies.

The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of Professional Interest Areas (PIAs), each focusing on a major scientific topic associated with ADRD. These PIAs include leading scientists from across the globe with substantial expertise covering crucial topics for ADRD. Previous reviews have documented factors contributing to or associated with ethnoracial disparities in ADRD research [17, 28, 29]. To expand on prior work on the topic, we leveraged the expertise of an international group of ISTAART scientists to synthesize a cross-PIA white paper to accomplish the following goals:

1.   Provide a concise "state-of-the-science" report of ethnoracial factors across PIA foci.

2.   Provide recommendations regarding most immediate needs to advance ADRD science across ethnoracial populations.

3.   Provide a working model that provides specific key foci for advancing the field of health disparities in ADRD

This whitepaper is organized into the follow sections with specific contributions from each ISTAART PIA.

- Factors related to disease detection and biomarkers

   ○   Reserve, Resilience and Protective Factors PIA

- ○ Diversity and Disparities PIA

- ○ Neuroimaging PIA

- ○ Electrophysiology PIA

- ○ Biofluid Based Biomarkers PIA

- ○ Immunity and Neurodegeneration PIA

- Factors related to interventions and methods

  - ○ Clinical Trials Advancement and Methods PIA

  - ○ Non-pharmacological Interventions PIA

- Ethnoracial factors related to subjective concerns and affect in ADRD

  - ○ Subjective Cognitive Decline PIA

  - ○ Neuropsychiatric Syndromes PIA

- Ethnoracial factors related to atypical AD and other ADRD

  - ○ Atypical Alzheimer's Disease and Associated Syndromes PIA

  - ○ Down Syndrome and Alzheimer's Disease PIA

  - ○ Vascular Cognitive Disorders PIA

- Other factors related to cognitive impairment and dementia

  - ○ Perioperative Cognition and Delirium PIA

  - ○ Nutrition, Metabolism, and Dementia PIA

  - ○ Technology PIA

- List of recommendations to collectively and collaboratively advance the gaps identified by the respective PIAs

  - ○ All PIAs, including specific methodological considerations from the Design and Data Analytics PIA

- Advancing the Science of Health Disparities in ADRDs

  - ○ All PIAs

1. Factors Related to Disease Detection and Biomarkers in ADRDs

a. The influence of ethnoracial factors on reserve, resilience and protective factors.

Cognitive reserve is a heuristic to help explain individual differences in brain health and cognition relative to aging and brain disease [30–32]. These individual differences could reflect higher capital (higher to start with), better maintenance (lower decline) or greater resilience/tolerance and compensation capacities [30–32].

Very little research has assessed whether cognitive reserve differs across ethnoracial groups. Because ethnoracial groups are characterized by distinct social and behavioral practices, and

may have different genetic background, differences in reserve can be expected as a function of ethnoracial factors. Differences in cognitive reserve might in turn explain differences in the prevalence or incidence of AD, or in the age at disease onset between ethnoracial groups [29, 33] [5,6]. For instance, some ethnoracial populations are characterized by a lack of formal education, which is strongly associated with lower cognitive reserve [34]. However, years of education has been shown to be a poor reflection of the value of educational experience and native ability among ethnoracial groups, while literacy level may be more strongly associated with reserve in diverse cohorts [35, 36].

Differences in reserve across ethnoracial groups may be reflected in differences in a) the baseline capital (of brain health and cognition); b) the maintenance of this capital over time; and c) the resistance/resilience of cognitive performance to pathological brain changes. Empirical evidence for the two first cases (higher capital or better maintenance), may manifest both by differences in brain health markers and in cognitive performance in diverse ethnoracial populations. Difference in maintenance may be more accurately assessed longitudinally by measuring the rate of brain or cognitive changes over time in different groups. For instance, African Americans have been found to have lower level of global cognition at baseline, but a slower rate of cognitive decline over time, compared to non-African Americans [37]. An important goal that emerges is to understand the relative contributions of different genetic and socio-behavioral/lifestyle factors on the observed differences among ethnoracial groups in markers of brain health or cognition.

Finally, differences in resilience/resistance to pathology amongst ethnoracial groups may reflect different relationships between brain health and cognitive performance, e.g., higher levels of brain pathology for a given degree of cognitive impairment. This was found in one previous study showing lower CSF phosphorylated -tau (p-tau181) and total tau (t-tau) levels in African Americans compared to Caucasians, independent of cognition [15].

b. The influence of ethnoracial factors on diversity and disparities.

Mungas (2006) presented a model illustrating how ethnoracial factors, aging, and disease may influence cognitive ability through the interplay of environment, genes, and brain structure [38]. Based on this model, the influence that ethnicity exerts on cognitive functioning would be modulated by the relationships of multiple factors. In this section, we address these factors from the perspectives related to the examinees (i.e., individuals with ADRD and caregivers), the examiners, and the specific assessments used.

Cognitive testing is important for detecting, monitoring and distinguishing differences amongst ADRD. Most cognitive measures are influenced by linguistic, educational, or cultural factors, which affect the ability to accurately identify cognitive impairment and decline in diverse individuals. One of the challenges in assessing ethnoracial groups is limited formal education and/or high illiteracy rates and/or cultural nuances to learning and ways of thinking and solving problems. Lower education has consistently been associated with worse health status on a number of outcomes, including dementia. Reading measures created in one language do not necessarily translate well into other languages due to a variety of factors [39]. Translating tests across cultural boundaries may not capture the diverse impact that cultures have on cognition [40, 41]; however, it has been reported that

appropriate adjustment for ethnicity can improve validity of test findings[42, 43]. Neuropsychologists need training to work with minority groups [17, 44]; however, the number of neuropsychologists with competency to work with ethnoracial groups and/or possess proficiency in non-English languages is limited [44, 45].

Finally, there are factors related to the cultural validity, cost-effectiveness, representativeness, and availability of reliable norms of neuropsychological testing itself. It remains unclear whether translated tests measure constructs retain a similar meaning within and across cultural groups. As Luria [46] noted, tests developed and validated for use in one culture, frequently result in experimental failures and are invalid for use with other cultural groups. For instance, one study showed that relative difficulty of sub-items on the widely used Mini-Mental State Exam (MMSE) could differ due to cultural factors between the U.S. and Japan, which could affect sensitivity and specificity of identifying those with cognitive impairment [47]. While many groups have attempted to generate appropriate normative data across ethnic groups [48–50], the numbers of such norms remain small and the availability of norms for individuals with little education remains limited [48, 50]. Cost-effective screening tools that have little reliance on background education would be of tremendous utility to large-scale longitudinal epidemiological studies of diverse ethnoracial groups [45], which is preferable to different sites using different tests or different versions of the same tests.

c. The influence of ethnoracial factors on neuroimaging biomarkers.

The utilization of neuroimaging biomarkers in ADRD has become increasingly important as structural, functional and molecular imaging have led to earlier diagnosis [51–53]; disease staging, including prodromal and preclinical stages [54, 55]; and identification of individuals for clinical trial participation [56]. However, while great strides have been made in the field of AD neuroimaging, relationships between biomarkers and ethnoracial factors remain understudied. For example, the 2012 demographic report from the Alzheimer's Disease Neuroimaging Initiative (ADNI) describes the sample as comprising fewer than 5% African American or Hispanic participants [57]. As with ADNI, the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging [58] does not contain broad representation from ethnoracial populations. However, the recently initiated Study of Latinos Investigation of Neurocognitive Aging (SOL/INCA) and Health & Aging Brain among Latino Elders (HABLE) studies will soon offerunique opportunities to study imaging markers related to cognitive aging among U.S. Latino adults and seniors.

Only a few studies have explored the link between ethnoracial factors and brain structure along the AD continuum, and their findings have not been consistent. DeCarli et al., examined ethnoracial differences in brain volume and cerebrovascular disease (CVD) and found greater total brain volume in Hispanics compared to non-Hispanic whites (nHW) regardless of diagnosis, and found no ethnoracial differences in CVD measures [59]. Similarly, the Chicago Health and Aging Project did not find significant interactions between race and CVD [60]. While the Washington Heights-Inwood Columbia Aging project (WHICAP) demonstrated greater brain volume in Hispanics and African Americans compared to nHW, they also demonstrated significantly higher CVD in these groups

compared to nHW [61]. The Atherosclerosis Risk in Communities (ARIC) study has similarly demonstrated that African American race was a predictor of an increased number of silent infarcts [62]. Additionally, ARIC demonstrated higher rates of atrophy in African Americans at baseline and a greater worsening of atrophy over time [62]. Many of the ethnoracial differences in CVD are linked to differences in clinical risk factors, but it is worth noting that some of these risk factors, like smoking, conferred a more than 4-fold greater risk of CVD in African Americans compared to nHW [63]. There are also inconsistencies in the research literature with some work failing to identify ethnoracial differences in the relationships between brain function and cognition [59, 64], while others have shown a significant relationship between cognitive dysfunction and structure [65, 66]. WHICAP demonstrated that MRI predictors of cognition differed across ethnoracial groups. For example, CVD was associated with worse language and executive performance in African Americans compared to nHW [65].

Over the last decade, positron emission tomography (PET) imaging has played a seminal role in the field of AD neuroimaging, allowing for accurate *in vivo* detection of beta-amyloid pathology in the brain [67], advancing the field significantly. However, few published studies have systematically explored ethnoracial differences in amyloid PET and no studies have been published to date in ethnoracial diverse populations that assess the more recently developed tau imaging agents. The ARIC study demonstrated significantly increased odds of elevated brain amyloid in African Americans, after adjusting for other risk factors like *APOE* ε4, age and CVD [68]. Interestingly, the effect size was similar to the well-established increased risk of amyloid positivity in *APOE* ε4 carriers [69]. Additionally, when examining a multi-ethnic group of non-demented older adults (n=116), baseline cognitive scores were not associated with amyloid burden. However, higher amyloid levels were associated with faster longitudinal cognitive decline among African Americans and *APOE* ε4 carriers [66]. These data highlight the need for not only neuroimaging studies with more diverse samples but also a better understanding of the interaction between ethnoracial factors, risk factors, genetics, and neuroimaging biomarkers in these populations.

d. The influence of ethnoracial factors on EEG/event-related potentials-based biomarkers.

Compared with structural, molecular, and functional neuroimaging techniques, measurements of brain electroencephalographic activity (EEG) during sleep, resting state (rsEEG), and sensory and cognitive-motor events (event-related potentials, ERPs) are less-invasive, more readily accessible, and cost-effective. EEG also has the unique temporal resolution (i.e., milliseconds) to explore abnormal oscillatory or dynamical neurophysiological mechanisms of brain neural synchronization and functional connectivity in individuals with neurological disease and animal models of diseases [70].

EEG biomarkers are promising candidates for an instrumental assessment of neurophysiological brain functions across disease progression and intervention in AD populations [71]. Previous EEG biomarker research with ethnoracial groups is inconclusive. A study carried out in 236 AD patients reported a higher risk of unprovoked seizures and epileptiform EEG activity in African Americans than nHWs [72]; however, this ethnoracial

effect was not replicated in a larger number of individuals diagnosed with AD (N = 453) [73].

Motivation for future EEG investigations testing possible ethnoracial differences in AD rest upon previous evidence. An EEG study on sleep spindles in healthy individuals (N = 11,630) reported differences between nHWs and African Americans in several EEG features characteristic of sleep architecture, though these differences decrease with advanced age [74]. Recent reports have unveiled abnormal sleep and circadian rhythms with cognitive change and AD [75], suggesting race/ethnic factors may translate to differences in AD phenotypes. These studies suggest ethnoracial and genetic factors impact EEG activity.

e. The influence of ethnoracial factors on biofluid-based biomarkers.

The impact of ethnoracial factors on biofluid-based biomarkers is well-documented across numerous disease processes [76–88]. Despite the extensive literature on biofluid-based biomarkers in other areas, the study of the link between ethnoracial factors and biofluid-based biomarkers in ADRD is nearly non-existent [89, 90]. A meta-analysis of genome-wide allelic association study (GWAS) data from several cohorts that included over 500 Hispanics AD cases to cross-validate four of the top previously identified AD genes, found that *APOE* ε4 genotype was significantly associated with AD status among all ethnic groups. However, CLU, CR1 and PICALM were only associated with AD status among nHWs [89]. Additionally, *APOE* ε4 has been found to be *less frequent* among Mexican Americans diagnosed with MCI and AD [14, 91]. The ARIC study reported overlapping and race-specific genetic markers linked to plasma beta-amyloid levels when comparing African Americans and European Americans [92]. Ting et al. presented data on a novel PSEN1 mutation associated with early-onset AD in African American woman [93], whereas a different mutation for early-onset AD among Caribbean Hispanics has been identified [94]. Regarding non-genetic blood-based biomarkers, plasma biomarkers of $A\beta_{40}$, $A\beta_{42}$ and tau were recently examined among an ethnically diverse sample of females clinically diagnosed with amnestic mild cognitive impairment (aMCI) [95]. While increased $A\beta_{42}$ levels were associated with incidence of aMCI among Hispanics, this association did not hold for nHWs or African Americans. Plasma $A\beta_{40}$ levels were significantly higher among Hispanic aMCI cases as compared to Hispanic controls; this difference was not found among African Americans. However, plasma total tau levels were significantly decreased among African American aMCI cases, but was not found among nHWs or Hispanics.[95]. C-reactive protein (CRP) levels have been found to be significantly elevated among Mexican Americans diagnosed with AD and MCI as compared to non-Hispanics [96]. Further, the overall proteomic profile indicative of AD has been found to be different between Mexican Americans and nHWs [16, 97].

Despite the extensive literature on diagnostic biomarkers of AD in CSF, there has been only one study specifically examining the impact of ethnoracial factors on these diagnosticmarkers. Howell et al. [15] recently recruited n=135 older adults (n=65 African American, n=70 nHW) spanning normal cognition, MCI and AD, all of which underwent lumbar puncture for an assay of CSF-based AD pathological markers. The ethnoracial groups were not significantly different with regards to age, gender or education. African

Americans had lower levels of CSF p-tau181, t-tau and $A\beta_{40}$ levels when compared to nHWs, whereas $A\beta_{42}$ levels did not vary by ethnoracial group [15]. These results suggest that absolute cut-scores on these markers may be impacted by ethnoracial factors and highlight the need for additional work examining the impact of such factors on CSF-biomarkers of ADRD.

f. The influence of ethnoracial factors on immunity and neurodegeneration.

While ethnoracial factors have not been explored with specific reference to the immune system in AD, there is a significant body of data that has explored immune differences across ethnoracial groups in other disorders and suggests further investigation. In vascular disease, for instance, ethnoracial factors impact expression of adhesion molecules, known to attract lymphocytes to the endothelium contributing to the formation of atherosclerotic plaques. Elevated soluble levels of many factors including ICAM-1 and VCAM-1 are associated with increased risk of coronary artery disease, and more generally, atherosclerosis. Surprisingly, lower levels of soluble ICAM-1 and soluble VCAM-1 were found in individuals of African origin than nHW or South Asian populations [98, 99]. Importantly, these results remained significant when controlled for homocysteine and socio-economic status. These findings were replicated [100] where soluble ICAM-1 and soluble VCAM-1 were decreased in African Americans as opposed to nHW Americans. The results are counter-intuitive given the increased risk of heart disease in the African American population.

C-reactive protein (CRP) has long been used as a determinant of systemic inflammation, and is frequently measured in the study of many diseases including CVD, AD and vascular dementia [101]. CRP has been shown to be significantly elevated in the non-Hispanic African American population as opposed to nHW [102]. In another study, the CRP elevations in African Americans were attenuated significantly when controlling for socio-demographic and health variables [103].

Inflammatory cytokines have been explored with respect to ethnoracial differences. Circulating levels of IL-6 have been shown to be elevated in African Americans compared with nHW in a cross-sectional study of 508 men and women with 38% African American participants. The IL-6 elevation remained when controlling for socio-demographic and health variables. In the same study, IL-10 and TNFα were found to be unchanged when comparing African Americans and nHW [102]. Other studies examining cytokines present disparate findings, most likely attributable to the extremely small sample sizes; some as low as n=10 per group. A good example is IL-1β, where a study concluded IL1β levels were elevated in African Americans, but there were 83 African Americans and 24 nHWs in this study [104]. Another study found a *non-significant* increase in IL1β in African Americans as opposed to nHWs, which was in a sample size of only 10 per group [105]. Finally, a study with 48 nHWs and 47 African Americans found that there was no difference in IL-1β levels [106]. These disparate findings speak to the need to have sufficiently powered and controlled studies to achieve reliable data and strong conclusions.

A recent study explored the impact of income and educational attainment in ethnoracial disparities in inflammatory risk as it relates to cardiovascular disease [103]. The results

showed that higher CRP levels in non-Hispanic African Americans and Mexican Americans compared to nHW, were explained entirely by educational attainment. The authors concluded that studies should move beyond examining income to include other socio-economic factors, with education level being a key part of this. There are no studies examining neuroinflammation in the brain, and therefore we understand very little regarding ethnoracial microglial differences. The systemic inflammatory differences, and the immune changes related to cardiovascular disease, highlight the potential for significant differences that could have implications for disease progression and treatment in ADRD.

2. Factors Related to Interventions and Methods

a. Ethnoracial factors related to clinical trials.

There is a well-established widespread failure to successfully enroll diverse ethnoracial populations into clinical trials for ADRD such trials. One review found that fewer than 1% of volunteers recruited into AD trials (over 11,000 patients) were of Hispanic ethnicity and 2% were African American [107]. In general, enrollment of diverse ethnoracial groups remains less than 5% of the trial subjects [108]; however, in the U.S., NIH-funded trials appear to have higher representation of diverse populations when compared to industry-sponsored trials [107]. Despite this, novel approaches for recruitment are urgently needed [109]. In addition to lack of representation in clinical trials, underrepresented individuals diagnosed with AD are less likely than nHWs to be prescribed Regulatory (e.g., U.S. Food & Drug Administration, European Medicines Agency) approved therapeutics [110].

Ethnoracial factors are frequently covaried in statistical analyses rather than outcomes being reported by subgroup [111, 112]. These factors alone make understanding the impact of ethnoracial factors on therapeutic response difficult. ADNI and AIBLE studies are frequently used for estimating sample size for clinical trials, but as noted earlier, they lack ethnoracial diversity and the estimates might not be valid if trials were conducted among non-nHWs. Lack of diversity could also mask potential ethnoracial differences in efficacy due to different biological mechanisms as discussed earlier, in addition to different rates of attrition/drop out and medication adherence across groups. One study, which investigated the structural MRI regions of interest associated with MCI, showed that once the attrition bias is controlled using propensity score models, fewer regions were found significant [113]. This study underlines the potentially large bias in study results if attrition bias is neglected and suggests that documenting rate of attrition for ethnoracial groups in trials is important.

Utilizing technologies to monitor disease progression (potential trial outcomes) or identify those who develop cognitive impairment (study enrichment) has generated great interest in ADRD. It is not well known whether ethnoracial differences may explain willingness in volunteering for trials that involve modern technologies and naturalistic methodologies for data collection (e.g., in-home and in-vehicle monitoring, wearable devices, internet/webcam). One study found a volunteer bias for the RCT, where Internet, webcam, and personal computers are being used intensively [114]. Identifying potential volunteer bias before the study recruitment begins by closely assessing past studies or distributing questionnaires, which allows for assessment of the characteristics of potential participants,

could aid diversification of study participants, especially when specific types of technologies are involved.

Significant barriers to enrollment of diverse groups into trials must be addressed. For example, recent work has found that African Americans are less likely to agree to participate in preclinical or asymptomatic AD trials [115] and have higher dropout rates in AD trials when compared to nHWs [116]. Regardless of these barriers, it is important that the research community continue to improve recruitment of diverse populations into clinical trials of ADRD. This will increase the generalizability of study results as well as investigate potential biological differences across ethnoracial groups and their effects on drug efficacy, adverse events and drop out/adherence. Recent efforts by the National Institute on Aging, with support of the Alzheimer's Association, are developing a national strategy for clinical study recruitment and retention, with a direct emphasis on local and diverse recruitment and retention strategies [117].

b. The influence of ethnoracial factors on non-pharmacological interventions.

Non-pharmacological intervention research examines the effect of therapeutic interventions such as cognitive training, exercise, functional retraining, and psychological supports (e.g. counseling or meditation), to delay and/or prevent the onset of ADRD symptoms, or remediate their impact [118, 119]. Relative to pharmacological treatments, non-pharmacological interventions are more likely to target not only primary symptoms (e.g., cognitive and functional decline), but also secondary symptoms that may not be caused directly by disease, but that lead to excess disability (e.g., stigma, anxiety, reduced self-esteem). In this vein, non-pharmacological interventions also seek to maintain the individual's autonomy and the highest quality of life possible during dementia-related cognitive and functional decline. Researchers working with distinct ethnoracial population groups have developed successful non-pharmacological interventions for these groups such as the "Six Arts" framework developed from a Confucian philosophy which emphasizes art, music and math to improve everyday function [120]. However, less understood is the generalization of non-pharmacological intervention studies from one sub-group to others, especially those with different access, experiences and beliefs about medical care.

Sociocultural factors may have an impact on differential outcomes in non-pharmacological intervention research at different methodological levels. These factors might hinder the ability of non-pharmacological intervention researchers to *recruit* participants and caregivers from diverse ethnoracial groups. Sociocultural factors might influence the *retention* of participants in activities, in particular when activities are less suitable for diverse groups, and in consequence might influence the *outcome* of the effectiveness of such interventions. In an analysis of the Resources for Enhancing Alzheimer's Caregiver Health (REACH II) trials, researchers concluded that the negative effects of ethnoracial factors on primary outcomes were diminished after controlling for demographic variables such as level of education and relationship of the caregiver to the person with dementia [121]. Further, evidence suggests that beliefs, expectations, quality of life, and even intent-to-participate in non-pharmacological interventions is impacted by ethnoracial factors in some chronic conditions,

[119, 122, 123], thereby providing support for the need to study the impact of ethnoracial factors in non-pharmacological interventions in ADRD.

3.   Ethnoracial Factors Related to Subjective Concerns and Neuropsychiatric Symptoms in ADRDs

a.   Subjective cognitive decline across ethnoracial groups.

One of the primary challenges ahead of prevention and treatment interventions in ADRD is the ability to screen those at higher risk of developing dementia. The concept of subjective cognitive decline (SCD) or perceived and reported decline in cognitive abilities (previously known as subjective memory complaints or SMCs) has been proposed to unify the research conceptualization of the earliest non-clinical stage, with potential significance for prevention trials in those with higher risk of AD [124]. In fact, SCD has been associated with AD-related neuropathological processes in non-clinical cohorts [125], and has been identified in individuals aged 30 years and above [126], which provides a 20–30 year window for potential prevention approaches.

SCD prevalence, incidence and final outcomes in ethnoracial groups are areas that have received little attention. One of the very first, yet largest studies of older African Americans (n=1250) showed that 48.3% of these individuals reported memory problems [127]. The authors concluded that memory complaints in this group could be explained by health problems, stressful life events, hearing loss or depressive signs and symptoms [127]. A more recent publication on a smaller cohort of African Americans (n=150) reported that a third of participants complained about their memory and cognitive abilities, and their reported cognitive difficulties were mostly associated with increased health problems, depression, and social problems [128]. Interestingly, a previous publication reported a discrepancy between objective cognitive abilities and SMCs reported by African Americans, where they seemed to report lower numbers of SMCs in the presence of objectively more impaired abilities [129]. This finding was reported by a more recent study reporting "unique patterns of variability" in SMCs of African Americans and the relationship between SMCs and psychological wellbeing [130]. However, it seems that in non-depressed African Americans, SMCs are more related to cerebrovascular risk factors [131].

The prevalence and incidence, as well as the outcomes of SCD in other ethnoracial groups have also been less investigated. For example, in a memory clinic cohort, Hispanic individuals reported more cognitive complaints than their nHW peers [132]. In a recent study of cognitively normal, community-dwelling Mexican Americans (n=319), it was found that those with SCD exhibited poorer cognition and were more likely to endorse affective dysfunction [133]. A qualitative study of SCD in 6 different ethnic groups including African Americans, American Indians, Chinese Americans, Latinos, Vietnamese Americans, and nHWs indicated that most of the participants were concerned about their cognitive functioning as they age [134]. However, this study did not provide detailed information on the prevalence, incidence and follow up outcomes for the different ethnoracial groups.

b. Neuropsychiatric symptoms of AD in ethnoracial groups.

Neuropsychiatric symptoms (NPS), which include symptoms such as depression, agitation, and psychosis, are common in dementia and are associated with faster disease progression, diminished quality of life, and early institutionalization [135]. Racial and ethnic disparities in prevalence, and knowledge of NPS exist in the U.S.; however, few studies of these disparities of NPS in AD exist, and they primarily focus upon NPS prevalence [136, 137]. Since NPS create much distress for caregivers and care recipients, it is critical to determine their impact upon different ethnoracial groups.

The Neuropsychiatric Inventory Questionnaire (NPI-Q) is the most common measure of NPS used in AD studies [138–141]. Existing literature suggests incidence disparities of NPS in AD among different ethnoracial groups. African-Americans may experience hallucinations more frequently [136, 137], and non-institutionalized African American and Latino American's with dementia have more frequent behavioral symptoms than nHW [138]. Another study found that being from a member of some ethnoracial minority groups was associated with psychosis as well [139]. A higher presence and severity of NPS have been found among Latinos diagnosed with MCI and AD [14, 20, 140], which suggests that they may seek treatment at more advanced stages of AD [138, 141]. However, nHW have been found to exhibit higher levels of apathy [136, 139]. Asian Americans diagnosed with AD showed frequent emotional disinhibition in one study [136], but more literature on NPS in that demographic is needed. No studies on the prevalence of NPS in American Indians with AD currently exist.

Regarding knowledge of AD-related NPS, Korean Americans knew less about AD behavioral changes than about cognitive changes, and Latino caregivers (not specified by ethnicity) could not attribute NPS to AD specifically [142, 143]. No literature exists of African Americans' knowledge of NPS in AD, but this group appears to view NPS as a source of stress in caregiving [144]. African Americans may cope with NPS through their faith and assistance from loved ones and may find behavioral interventions centered on emotional distress to be less useful [145, 146]. No studies were found on access to AD care for NPS specifically, but minority elders have lower access to mental healthcare relative to nHW and are institutionalized for AD less frequently [147, 148]. Nevertheless, a cultural emphasis on family, respect for elders, and perceptions of AD symptoms as "natural" parts of aging may cause members of those minority groups to take more time before seeking external care for NPS [21, 24]. African Americans are less frequently prescribed medications overall for AD and discontinue AD medication more frequently [149–151]. The only study to look specifically at medication use for NPS in AD (antipsychotics) among different racial groups found that the usage was higher among Hispanic Americans, likely due to the higher prevalence of NPS in that population [152].

Bridging gaps in NPS prevalence, knowledge, and care should involve creating tailored interventions for a group delivered by interventionists who understand (and ideally come from) cultural dynamics [146, 153, 154], as well as through bettering educational outreach to populations with a lower understanding of NPS. Additionally, much more research is needed to understand the ethnoracial, systematic, and possible genetic influences on NPS occurrence, neuropathology, and treatment.

4. Ethnoracial Factors Related to Atypical ADRDs

a. The impact of ethnoracial factors in atypical AD and associated syndromes.

Atypical AD was acknowledged in the revised diagnostic guidelines for AD in 2011, [155], and has since become an umbrella term encompassing non-amnestic clinical presentations, early (young) onset AD, and neuropathologically defined subtypes of AD (*i.e.*, hippocampal sparing or limbic predominant) [156–160]. Clinical and neuropathologic studies suggest that younger age and absence of an *APOE* ε4 allele are associated with greater likelihood of atypical AD [161–164]. Regardless of etiology, approximately 5–10% of individuals present with non-amnestic mild cognitive impairment (naMCI) [165–167] and 20–33% of individuals present with atypical AD [168–170]. Compared to typical AD, clinical diagnosis of atypical AD is often delayed and very little is known about its pathogenesis, risk factors, natural history, and response to treatments [171, 172] overall, and more so across ethnoracial groups.

The estimated prevalence and incidence of naMCI in non-Hispanic African Americans, is approximately 16–18% [165, 173] and 3–4 per 100 person-years, [165, 174] respectively, with up to a two-fold increased risk compared to nHW even after controlling for sex and education [165, 175]. The two-fold increased risk is suspected to be driven by higher rates of cardiovascular risk factors among African Americans, [176–178], suggesting a primary or superimposed vascular etiology. A large cross-sectional study of community-dwelling Colombian adults showed that naMCI was more common in young-onset dementias and in individuals with lower education [179]. Another study investigating the dysexecutive variant of AD identified that after controlling for covariates (vascular risk, *APOE* ε4, and global cognition), the MCI dysexecutive subgroup was older, less educated, and more likely identified as African American than the amnestic MCI subgroup. In contrast, the AD dysexecutive subgroup was younger than the amnestic AD subgroup and did not differ in education or ethnicity [180]. These results suggest there may be an even more nuanced aspect related to clinical progression that may need to be accounted for in ethnoracial studies.

With respect to associated syndromes that may or may not be related to AD pathology, the prevalence of dementia among 2011–2013 Medicare beneficiaries ages 68 showed that FTD was clinically diagnosed in 0.6% of African Americans, 0.7% of Hispanics, 0.8% of Asian/Pacific Islanders, 0.6% of American Indian or Alaska Natives, and 1.1% in other/unknown non-White groups [181]. A study examining a community sample of Hispanics ages 55 found that approximately 9% had clinical diagnosis of FTD and 3% a diagnosis of dementia with parkinsonian features [182]. A study investigating African Americans clinically diagnosed with FTD revealed AD pathology along with *PSEN1* (M139V) and *MAPT* polymorphism in exon 7 (A178T) mutations, suggesting that *M139V* may present differently among different ethnoracial groups [183]. Studies also show that *PSEN2* is closely involved in FTD [184, 185] and is also found in Asian [186–188] and African populations [188–191]. Low-frequency coding variants for genetic susceptibility to AD and FTD have also been reported in African American, Asians, and Hispanics [192, 193].

Overall, studying clinicopathologic differences in atypical AD poses great challenges due to their low disease prevalence, as well as to the interrelated biopsychosocial and cultural factors affecting participation in clinical studies and health outcomes in ethnoracial groups. A paradigm incorporating those factors is necessary to better understand and improve dementia treatments in these historically underserved, ethnoracial populations [194].

b. The influence of race and ethnicity in Down syndrome.

Individuals with Down syndrome (DS) are at high risk for developing AD compared to the general population [195]. All individuals with trisomy 21 show AD neuropathology by age 40 and over 90% show dementia in the seventh decade [196]. The International Workgroup suggests DS may be a genetically determined atypical AD [197].

There are numerous barriers to early diagnosis of dementia in DS that reflect an interaction between ethnoracial and health disparities. For example, symptoms of dementia may be missed or not identified [198]. Often there are differing symptom presentations in people with DS relative to sporadic AD and there are concerns about the appropriateness of the diagnostic tools [199]. Challenges of dementia diagnosis in DS within the context of intellectual disability (ID) require specialized expertise and tools [200].

In a preliminary analysis, the incidence of MCI and of AD was 6% higher among African Americans with DS than among nHW adults with DS (data from the Aging and Dementia in Adults with Down Syndrome Study, W. Silverman). Age at onset of MCI did not differ between African American and nHW adults with DS, while age at onset of AD was slightly earlier among African-Americans, suggesting a more rapid decline in cognitive function after onset of MCI. In the general population, the higher rates of AD among African-Americans than among nHWs has been related to an increased prevalence of cardiovascular risk factors and cerebrovascular disease, which in turn may elevate risk for AD. These factors are less likely to influence risk among adults with DS [195]. Current cohorts under study have relatively few minority participants and few studies have examined ethnoracial disparities in risk factors for dementia.

Mortality rates also vary across ethnic groups in DS; disproportionately more African Americans with DS die as young adults [201]. The ability to determine contributors to the age of onset of dementia in individuals with DS is confounded by differences in age at death across different ethnoracial groups. Disparities are also present in the care of individuals with DS and dementia. In the U.S., access to group homes (related to intellectual disability) rather than dementia special care units is common as group homes are reported to provide care in a home-like environment, with more economical costs [202, 203]. However, gaps in services and unmet service needs are reported for adults with DS in rural/remote settings and their caregivers rely on informal support [204–206]. In the United Kingdom, aging-in-place models are encouraged if appropriate support is available. The majority of adults with intellectual disability in the U.S. live at home, and this is more common among diverse ethnoracial groups (e.g. African Americans, Hispanics) with DS [207–209]. These differences in care models impact the caregivers, with poorer health reported for caregivers of individuals with DS who are also minorities [208, 210, 211], which in turn could be a reflection of socioeconomic status and possibly cultural practices. Collaborative studies with

combined and harmonized cohorts of older adults with DS are needed to determine differences in risk factor profiles and to provide accurate estimates of any differences in risk for AD and rates of progression after onset.

c. Ethnoracial factors and Vascular Cognitive Disorders.

Vascular Cognitive Disorders (VCD) are caused and exacerbated by health disparities experienced by ethnoracial groups. Globally, these disparities can be attributed partially to burgeoning obesity, combinations of lifestyle factors associated with poor vascular health, and unknown genetic and lifestyle susceptibilities among increasing immigrant populations. Being overweight and obese are cornerstones of vascular risk, leading to hypertension, type 2 diabetes, CVD, cerebrovascular disease, and stroke, as well as cognitive impairment and multiple etiologies dementias.

The prevalence of overweight and obesity is over 50% among adults in the U.S. and Europe, and within certain global urban centers such as the Brooklyn Borough of New York City, the prevalence is over 70%. Of the top 10 causes of death worldwide in 2015, [212] half are related to obesity, and account for approximately 1/3 of all deaths. These include ischemic heart disease, cerebrovascular disease/stroke, type 2 diabetes, and ADRD [212]. Vascular risk is a costly burden. In Brooklyn, hospitalizations and deaths from heart disease, diabetes, and disabilities are higher than the New York City average. Part of the reason is that ethnoracial minority adults typically present late, at more advanced stages of disease, and in nontraditional settings, such as the Emergency Department. Given adults from diverse ethnoracial groups also present with high vascular risk, they are even more compromised.

Stress is a major facilitator of vascular risk in ethnoracial minority groups. Stress is a cause, correlate and consequence of obesity. Not only do stress and obesity lead to downstream adverse vascular events, they are often accompanied by discrimination and unfair treatment, leading to additional stress responses [213]. Health disparities-related stress is also associated with ethnoracial differences, older age, family, employers, stigma due to ethno-race, sexual orientation, infectious disease status, employment status and/or sex/gender, poor access to health care services, built environment, lack of social support, depression, and anxiety [214]. Cumulatively, these stressors challenge social interactions and may manifest as inability to work, difficulties with personal relationships, [215] and challenges to social inclusion [216]. Over the life course, the cost of chronic exposure to fluctuating or heightened neuroendocrine responses resulting from repeated or chronic environmental challenges and social burden that an individual react to as being particularly stressful [216, 217] directly affects neural mechanisms contributing to cognitive function [218, 219].

Potentially modifiable vascular risk factors contribute to cognitive aging and risk and progression of ADRD through their effects on cerebral vasculature. The accumulation of small vessel cerebral vascular disease that results from years of exposure to vascular risk is best visualized on T2-weighted magnetic resonance imaging (MRI) as white matter hyperintensities (WMH). Increased WMH burden is associated with risk for development of ADRD [220–222] and progression of symptoms in ADRD [223], and is even evident in individuals with autosomal dominant AD up to 20 years prior to expected symptom onset [224]. The severity of WMH differs across racial and ethnic groups [61] and relates

differentially to specific cognitive outcomes as a function of race/ethnicity [225, 226]. Given the well-documented disparities in vascular risk factors, differences in cerebrovascular disease, and differential relationships with cognition between racial and ethnic groups, vascular disease is a major topic of focus with respect to racial and ethnic disparities in ADRD.

5. Other Factors Related to Cognitive Impairment and Dementia

a. Ethnoracial factors related to perioperative cognition and delirium.

Delirium is a focus for both research investigation and clinical care around the world. For example, one of the delirium screening tools, the Confusion Assessment Method (CAM) has been translated into 19 languages and used in over 4,000 original publications, demonstrating an active clinical and research interest in delirium [227]. Perioperative cognitive disorders may contribute to further cognitive decline and are known to be associated with poor outcomes. Despite this, there are few studies examining ethnoracial factors in either delirium or perioperative cognitive disorders, with studies being predominantly restricted to those who are fluent in English.

Campbell et al. [228] evaluated n=1,275 older adults   65 who were admitted to general medical hospital services. The goal of the study was to determine if race is a factor in the agreement between clinical documentation and screening results for delirium and cognitive impairment. The authors compared clinical documentation with scores on a screening measure (The Short Portable Mental Status Questionnaire; SPMSQ), and found that there were no differences in delirium documentation rates between African Americans and non-African Americans. However, African Americans had a higher adjusted odds ratio than non-African Americans for clinical documentation of cognitive impairment among those who screened positive for impairment on the SPMSQ, as well as among those who screened negative on SPMSQ.

One study examining the recorded diagnosis of delirium in acute inpatient units found that African Americans were more likely to receive a confusional diagnosis or an organic psychoses diagnosis as opposed to a diagnosis of delirium [229]. Individuals who received the diagnosis of organic psychoses had longer lengths of stay and higher rate of discharge to nursing homes. One of the potential explanations for these differences was that elderly African American individuals are significantly more likely to receive diagnosis of psychotic disorders compared to nHWs [230]. Another study examining the prevalence of delirium among older adults presenting with psychiatric complaints to an emergency department (ED), it was found that although minority individuals (African American and Hispanic) comprised 55.8% of the study cohort, 74.1% of delirium visits were comprised of minority individuals [231].

The most frequent etiology of delirium in sub-Saharan Africa (SSA) reported in the literature is infection including Human Immunodeficiency Virus (HIV), typhoid fever and malaria. However, the number of older adults is expected to increase by 64% in Africa in the next 15 years [232], and it is unknown whether the available expertise of diagnosing and treating delirium by health care providers in Sub-Saharan Africa (SSA) can meet the

increasing demand. In addition, with increasing access to higher levels of care in SSA, clinical entities such as Intensive Care Unit (ICU) delirium, which is a new concept to many physicians in these regions, are also emerging.

Cognitive decline associated with anesthesia and surgery is known to occur in more than 10% of individuals three months postoperatively [233] and has been termed postoperative cognitive dysfunction (POCD). POCD has been limited to predominantly English speakers due to limitations of existing neuropsychological tests, with some limited European languages included as part of the International Study of POCD [234]. POCD studies have been undertaken in some Asian populations but the majority of these are limited to very short follow-up of days rather than weeks, months or years [235]. It is unclear if POCD precipitates long-term cognitive decline, but it is known that POCD is associated with poor outcomes including increased risk of mortality as far as 7.5 years post-surgery [236]. Thus, it is important for future research to focus on ethnoracial factors that may contribute to perioperative cognitive disorders. The recent recommendations for new nomenclature should assist in facilitating this research agenda.

b. Ethnoracial factors related to diet and nutrition.

Diet is complex and varies considerably by ethnicity and socio-economic status [237–239]. It is well established that some ethnoracial groups experience diet-related disparities, and consequently have poorer nutrient profiles relative to nHWs [240, 241]. According to the U.S. Behavioral Risk Factor Surveillance Survey (BRFSS) [242], only 21.3% of African Americans consume fruits and vegetables 5 times per day, the lowest of any U.S. ethnoracial group. Similarly, in the third National Health and Nutrition Examination Survey, NHANES (1999–2002), non-Hispanic African Americans were 43% less likely than nHWs to meet fruit and vegetable guidelines[243]. These racial disparities differ by geographic region. For example, Hispanic groups consumed lower quality diets than nHWs, including more refined carbohydrates, and fewer vegetables and fruits [237, 238, 244], whereas in other studies Hispanics had higher quality diets, than either nHW or African Americans [239].

Poor diets and malnutrition are important contributors to cognitive impairment [245–247]. Nutritional deficiencies in older people, particularly in minority groups, are common, but studies across diverse ethnoracial populations are limited [247–250]. Randomized trials of nutritional supplements are needed to examine their impact on ethnoracial groups (e.g. African Americans) that have known nutritional deficiencies. Unfortunately, most randomized clinical trials of dietary supplements have not targeted populations with low nutrient status and trial results have been null overall [251]. Conducting dietary supplement trials in diverse ethnoracial populations with nutrient insufficiencies has the potential to close some of the ethnoracial disparities in ADRD.

The few studies that have examined dietary associations with AD and other brain neurodegenerative outcomes in multiethnic participants in most cases do not present their findings by race or ethnic group [246, 252–262]. Rather, these studies have reported p-values (usually null) for tests of effect modification by race/ethnicity [252, 253, 255, 256, 258, 262, 263]. This is inadequate as there are clear examples of nutrition having different

cognitive effects by ethnoracial groups as shown in the Healthy Aging in Neighborhoods of Diversity Across the Lifespan Study (vitamin E with various cognitive domains), and the Health, Aging and Body Composition study (the Mediterranean diet with cognitive decline) [264, 265].

Cultural differences in dietary practices pose methodological challenges in dietary assessment. Many food frequency questionnaires have not been designed and tested to accurately capture the foods, serving sizes, and meal preparations of different cultural groups [266]. Consequently, the dietary assessments from these studies likely produce biased estimates of nutrient relations with dementia, particularly for ethnoracial minority populations. To adequately address ethnoracial disparities in diet, nutrition and ADRD, it is imperative that greater attention is devoted to cultural validation of the dietary assessment methods.

c. Ethnoracial factors related to the development of technologies.

Technology for dementia has developed in several main areas: assessment of cognitive functions (e.g. [267]) and daily activities (e.g. [268]); direct cognitive (e.g. [269]) or behavioral support (e.g. [270]); monitoring (e.g. [271]); direct caregiving (e.g. [272]) and supporting caregivers (e.g. [273]). Different ethnoracial groups have been involved in the creation and testing of technologies, but the potential impact of these differences has not been explored. The focus of most research has been on the effectiveness or impact of the technology, with a lack of consideration of the role ethnoracial factors may play in utilization or impact potential.

Two key issues in development of technology for dementia relate to cognitive function and accessibility of technology. Understanding cognitive function is central to developing technology for individuals with dementia and this is where the lack of ethnoracial consideration is most apparent. Much technology development has focused on improving cognitive assessment [274] to enhance or improve dementia diagnosis. However, these studies have not reported on possible inclusion or on differences in cognitive performance and profiles [275] and rate of decline [276] in ethnoracial minority groups.

There is also limited information available on access to technology in ADRD. The 'digital divide' is an issue that reflects socio-economic factors, whereby lower income groups have less access to technologies. There are no existing survey data on access and use of technologies by people with dementia that consider ethnoracial factors. However, we can gain some insight from two large U.S. surveys that looked at the use of assistive technologies (AT) by different racial groups. Reed et al [277] conducted the Community Research for Assistive Technology Survey in California. They divided AT into three categories: High-tech (e.g. computers), Medium-tech (e.g. scooters) and Low-tech (e.g., magnifiers). The proportion of white respondents (23%) using High-tech devices was higher than Asian Americans (16%), African Americans (13%) and double the number of Latinos (11%) suggesting unequal access to the same technology [277]. This lack of access and awareness was echoed in a 2009 U.S. National Health Survey which looked at AT usage across groups with mobility, visual, auditory, and emotional disabilities [278]. Their findings suggested that income status, particularly receiving Medicaid or veteran's benefits, and

mental impairment reduced the likelihood of people using ATs [278]. To address these challenges, they proposed a list of changes including more cultural competency training, ensuring the attitudes and values are included in evaluating AT needs among underrepresented groups and designing effective outreach and health marketing appropriately tailored to different ethnoracial populations. In relation to dementia technology specifically, a survey of American and German family caregivers found low awareness of what technology is available for themselves or the people they care for [279]. Additionally, lack of access to broadband Internet, as well as limited availability of specialized technologies have been identified as key barriers to technology for dementia [280]. However, there are signs that the growing need to address these problems is starting to take hold through recent efforts to meet the needs of ethnic minority dementia caregivers through apps [281], online education [282], YouTube [283] and a survey of their preferences for technology [284].

Overall, there remains a significant dearth in research specifically designed to understand and address heath disparities in ADRD. Diverse ethnoracial populations remain underrepresented in studies across all areas covered by the PIAs. However, given the substantial amount of work that has been accomplished across these respective areas, there remain tremendous opportunities to rapidly advance the state of the science. Broad areas of immediate need, based on the information provided above, are provided below.

6. Recommendations for advancing the field of health disparities in ADRDs

As highlighted across each of the major topic areas and expert groups listed, there remain substantial knowledge gaps regarding the ADRD among diverse ethnoracial groups globally. The science of ADRD has advanced considerably over the last few decades and the same can be accomplished regarding an understanding of ADRD among diverse populations. First and foremost, the expertise of the various PIAs and global experts across fields needs to be leveraged to design and implement research programs to address the gaps identified in a rapid fashion.

Primary recommendations proposed by the working group are as follows:

- Develop specific health disparities models/frameworks and implement data driven strategies for targeted recruitment and retention of diverse ethnoracial populations into ADRD observational studies and clinical trials.

- Identify differing perspectives and views held by ethnoracial groups regarding ADRD research and interventions, in order to tailor appropriate methodologies for addressing gaps identified here as well as widely disseminating findings.

- Uniformly, examine the prevalence of specific life experiences/status (e.g. poverty, war/conflict, stigma, disability, sex, gender) and whether they play a role in ADRD disparities among diverse ethnoracial groups across countries.

- Create training modules, webinars, and related educational opportunities for researchers, payors, funders, community members and even research participants

to learn how to effectively develop diverse and inclusive study designs and recruitment and retention strategies in ADRD studies.

- Train practitioners and researchers (e.g. neuropsychologists, neurologists, geriatricians), including those from diverse ethnoracial groups, to implement culturally appropriate research methodologies (e.g. assessments, interviews, interventions) across different ethnoracial groups.

- Develop and validate appropriate research tools along with appropriate use and interpretative guidelines (e.g. normative references). This can include generation of instruments that can be utilized across groups, development of novel tools that are group-specific as well as the development of appropriate analytic methods for working across tools when needed.

- Establish collaborative infrastructure across existing longitudinal registries and cohorts that include diverse ethnoracial populations to address gaps identified here. Also, leverage existing infrastructures and knowledgebase for the establishment of additional targeted research cohorts to advance the field of health disparities in ADRD.

- Implement methodological strategies that enable post-hoc analyses across diverse groups, comparisons across longitudinal cohorts; consistently report ethnoracial subgroup data even when not analyzed; include refreshment samples in cohort studies to maintain statistical power – including addition of replacement for attrition in ongoing studies that are not representative of ethnoracial groups with diverse populations.

- Implement analytic methods to weigh observations from underrepresented groups to attenuate the impact of small sample size; investigate the impact of ethnoracial disparities on retention, attrition and mortality and consistently report ethnoracial subgroup data, even if such differences are not analyzed due to low group sample sizes.

- Develop and validate statistical models of risk and protective factors germane to ethnoracial groups, including complex interaction terms to better refine prevalence and incidence of ADRD between different groups.

- Employ structured "precision medicine" and "precision public health" approaches to combine, translate and share findings from ADRD research including ethnoracial groups across the world to target and continually refine diagnostics, disease monitoring, treatment, and development of new therapeutics.

- Include diverse ethnoracial groups in studies examining sociocultural, biomarker, biological mechanism, and all other aspects of ADRD science.

- Develop and disseminate educational materials regarding ADRD specifically focused on caregiver from diverge groups; include caregivers from diverse ethnoracial groups in scientific inquiries addressing caregiver and family needs.

7. Advancing the Science of Health Disparities in ADRDs.

As previously discussed, there are several gaps in the extant literature in many of the key areas of science currently being examined in ADRDs. Aside from the large gap in literature examining ethnoracial factors in ADRD documented by this working group, there is also no comprehensive framework to address the gaps. Specifically, the vast majority of the science conducted in the articles reviewed addressed one question at a time without the end in mind (i.e. a comprehensive understanding of the full complexity of ADRD, including ethnoracial factors). In order to advance the understanding of ethnoracial factors in ADRD, the field not only needs to directly test importance of ethnoracial factors, but also test these constructs within the context of the "big picture" including, but not limited to, factors such as gender, neuropathology (e.g. the 2018 NIA-AA research criteria for AD explicitly for testing of these new concepts in diverse populations), molecular biology, environmental factors and more.

If the comprehensive framework is to explicitly test and understand the complexity of ADRD, then more advanced analytic modeling approached are needed as is longitudinal data. Studies that iteratively propose a unique hypothesis, test the hypothesis, refine the question, and start-over using large-scale longitudinal data are needed. Multi-scale modeling, advanced artificial intelligence (AI) learning tools, structural equation modeling (SEM) are some of the tools that are explicitly designed to manage such large-scale and complex questions. The statistical/bioinformatics models can grow and expand iteratively as the hypotheses are tested, refined and reanalyzed. Many of these tools were refined in the human genome project, but have been applied to life-sciences at large-scale. The translational work in ADRD has begun to break down silos; however, the questions posed do not directly test the complexity of the problem faced. If these more complex tools are utilized, the complexity of ethnoracial factors, within the context of ADRD more broadly will become more in focus. This approach can lead to a precision medicine approach to treating and preventing AD.

In order to continue the momentum of this working group and other ongoing efforts, we propose that a formal meeting occur in conjunction with the National Alzheimer's Project Act meeting (or other meeting), specifically to address the advancement of health disparities in ADRD. This meeting would serve as a "think tank" on how to move the field forward rather than a venue for individuals to present their recent (or remote) findings. Experts from diverse backgrounds (epidemiology, health disparities, neuropathology, sociology, etc.) would be invited to discuss provide strategies for next steps to advance the field.

Authors

Ganesh M. Babulal[1,*], Yakeel T. Quiroz[2,*], Benedict C. Albensi[3], Eider Arenaza-Urquijo[4], Arlene J. Astell[5], Claudio Babiloni[6], Alex Bahar-Fuchs[7], Joanne Bell[8], Gene L. Bowman[9], Adam M Brickman[10], Gaël Chételat[11], Carrie Ciro[12], Ann D. Cohen[13], Peggye Dilworth-Anderson[14], Hiroko H. Dodge[15], Simone Dreux[16], Steven Edland[17], Anna Esbensen[18], Lisbeth Evered[19], Michael Ewers[20], Keith N. Fargo[21], Juan Fortea[22], Hector Gonzalez[23], Deborah R. Gustafson[24], Elizabeth

Head[25], James A. Hendrix[21], Scott M. Hofer[26], Leigh A. Johnson[27], Roos Jutten[28], Kerry Kilborn[29], Krista L. Lanctôt[30], Jennifer J. Manly[10], Ralph N. Martins[31], Michelle M. Mielke[32], Martha Clare Morris[33], Melissa E. Murray[34], Esther S. Oh[35], Mario A. Parra[36], Robert A. Rissman[37], Catherine M. Roe[1], Octavio A. Santos[38], Nikolaos Scarmeas[10,39], Lon S. Schneider[40], Nicole Schupf[41], Sietske Sikkes[42], Heather M. Snyder[21], Hamid R. Sohrabi[31], Yaakov Stern[43], Andre Strydom[44], Yi Tang[45], Graciela Muniz Terrera[46], Charlotte Teunissen[47], Debora Melo van Lent[48], Michael Weinborn[31], Linda Wesselman[49], Donna M. Wilcock[25], Henrik Zetterberg[50], and Sid E. O'Bryant[27,+] **International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association**

Affiliations

[1.]Department of Neurology and Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA [2.]Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [3.]Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Manitoba R2H 2A6, Canada; Department of Pharmacology & Therapeutics, University of Manitoba, Winnipeg, Manitoba R3E 0T6, Canada. [4.]Department of Radiology, Mayo Clinic, Rochester, MN, USA [5.]Department of Occupational Sciences & Occupational Therapy, University of Toronto, CA and School of Psychology and Clinical Language Sciences, University of Reading, UK [6.]Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy; Department of Neuroscience, IRCCS-Hospital San Raffaele Pisana of Rome and Cassino, Rome and Cassino, Italy [7.]Academic Unit for Psychiatry of Old Age, Department of Psychiatry, the University of Melbourne, Australia [8.]Syneos Health, Wilmington, NC, USA [9.]Nutrition and Brain Health Laboratory, Nestlé Institute of Health Sciences, Lausanne, Switzerland; Department of Neurology, Layton Aging & Alzheimer's Disease Center, Oregon Health & Science University, Portland, OR [10.]Taub Institute for Research in Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, NY [11.]Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France [12.]Department of Occupational Therapy Education, University of Kansas Medical Center, Kansas City, KS, USA [13.]Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA [14.]Gillings School of Global Public Health, University of North Carolina Chapel Hill, NC, USA [15.]Department of Neurology, Layton Aging and Alzheimer's Disease Center, Oregon Health & Science University, Portland, OR, USA [16.]Undergraduate Program of History and Science, Harvard College, Cambridge, MA, USA [17.]Department of Family Medicine and Public Health, University of California, San Diego, CA, USA [18.]Department of Pediatrics, University of Cincinnati College of Medicine & Division of Developmental and Behavioral Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA [19.]Melbourne Medical School, University of Melbourne, Australia [20.]Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany [21.]Medical & Scientific Relations, Alzheimer's

Association, Chicago, IL, USA [22.]Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain & Barcelona Down Medical Center. Fundació Catalana de Síndrome de Down, Barcelona, Spain. [23.]Department of Neurosciences and Shiley-Marcos Alzheimer's Disease Research Center, University of San Diego, CA, USA [24.]Department of Neurology, Section for NeuroEpidemiology, State University of New York – Downstate Medical Center, Brooklyn, NY, USA [25.]Sanders Brown Center on Aging, University of Kentucky, Lexington, KY, USA [26.]Adult Development and Aging, University of Victoria, British Columbia, CA [27.]Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA [28.]VU University Medical Center, Department of Neurology, Amsterdam Neuroscience, Amsterdam, the Netherlands [29.]Department of Psychology, University of Glasgow, Glasgow, Scotland, UK [30.] Sunnybrook Research Institute of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada [31.]Aging and Alzheimer's Disease, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia [32.]Departments of Epidemiology and Neurology, Mayo Clinic, Rochester, MN, USA [33.] Department of Internal Medicine, Rush University, Chicago, IL [34.]Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA [35.]Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA [36.]School of Social Sciences, Department of Psychology, Heriot-Watt University, UK; Universidad Autónoma del Caribe, Barranquilla, Colombia and Neuroprogressive and Dementia Network, UK [37.]Department of Neurosciences, University of California San Diego School of Medicine, CA, USA [38.]Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA [39.]Aiginition Hospital, 1st Neurology Clinic, Department of Social Medicine, Psychiatry and Neurology, National and Kapodistrian University of Athens, Athens, Greece [40.]Department of Psychiatry and The Behavioral Sciences, University of Southern California, CA, USA [41.]Department of Epidemiology, Mailman School of Public Health Columbia University, New York, NY, USA [42.]Massachusetts General Hospital, Department of Neurology, Boston, MA, USA [43.]Departments of Neurology and Psychiatry, Columbia University, New York, NY, USA [44.]Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK [45.]Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China [46.]Centers for Clinical Brain Sciences and Dementia Prevention, University in Edinburgh, Scotland, UK [47.]Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands [48.]Department of Clinical Research, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany [49.]Vrije Universiteit Amsterdam, Amsterdam, the Netherlands [50.]UK Dementia Research Institute at UCL, London, UK; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and

Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Acknowledgements:

References

1. Montgomery W, et al., Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan. Clinicoecon Outcomes Res, 2018 10: p. 13–28. [PubMed: 29343976]

2. Suzuki T, Health status of older adults living in the community in Japan: Recent changes and significance in the super-aged society. Geriatr Gerontol Int, 2018.

3. US_Census_Bureau, Facts for Features: O'der Americans Month: May 2017 2017.

4. Li F and Otani J, Financing elderly people's long-term care needs: Evidence from China. Int J Health Plann Manage, 2018.

5. George LS, et al., Morbidity pattern and its sociodemographic determinants among elderly population of Raichur district, Karnataka, India. J Family Med Prim Care, 2017 6(2): p. 340–344. [PubMed: 29302544]

6. Livingston G, et al., Dementia prevention, intervention, and care. The Lancet, 2017.

7. Prince M, W. A, Guerchet M, Gemma-Claire Ali M, Wu Y-T, Prina M, World Alzheimer Report 2015: The global impact of dementia an analysis of prevelance, incidence, cost and trends, A.s.D. International, Editor. 2015: London.

8. Anstey KJ, et al., Joining forces to prevent dementia: The International Research Network On Dementia Prevention (IRNDP). Int Psychogeriatr, 2017 29(11): p. 1757–1760. [PubMed: 28899450]

9. Patsiurko N, Campbell JL, and Hall JA, Measuring cultural diversity: ethnic, linguistic and religious fractionalization in the OECD. Ethnic and Racial Studies, 2012 35(2): p. 195–217.

10. Alesina A and Ferrara EL, Ethnic Diversity and Economic Performance. Journal of Economic Literature, 2005 43(3): p. 762–800.

11. Fearon JD, Ethnic and Cultural Diversity by Country*. Journal of Economic Growth, 2003 8(2): p. 195–222.

12. Yu L, et al., APOE epsilon4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans. PLoS One, 2017 12(7): p. e0180356. [PubMed: 28672022]

13. Roses AD, et al., African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles. Alzheimers Dement, 2014 10(6): p. 592–601.e2. [PubMed: 25260913]

14. O'Bryant SE, et al., Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis, 2013 33(2): p. 373–9. [PubMed: 22976076]

15. Howell JC, et al., Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers. Alzheimers Res Ther, 2017 9(1): p. 88. [PubMed: 29096697]

16. O'Bryant SE, et al., Biomarkers of Alzheimer's disease among Mexican Americans. Journal of Alzheimer's Disease, 2013 34(4): p. 841–849.

17. Chin AL, Negash S, and Hamilton R, Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord, 2011 25(3): p. 187–95. [PubMed: 21399486]

18. Alzheimer's Association. 2017 Alzheimer's disease facts and figures. Alzheimer's & Dementia 2017; Available from: http://www.alz.org/documents_custom/2017-facts-and-figures.pdf.

19. Cooper C, et al., A systematic review and meta-analysis of ethnic differences in use of dementia treatment, care, and research. Am J Geriatr Psychiatry, 2010 18(3): p. 193–203. [PubMed: 20224516]

20. O'Bryant SE, et al., Presentation of Mexican Americans to a memory disorder clinic. Journal of Psychopathology and Behavioral Assessment, 2007 29(3): p. 137–140.

21. Gray HL, et al., Ethnic differences in beliefs regarding Alzheimer disease among dementia family caregivers. Am J Geriatr Psychiatry, 2009 17(11): p. 925–33. [PubMed: 20104051]

22. Rovner BW, et al., Racial differences in the recognition of cognitive dysfunction in older persons. Alzheimer Dis Assoc Disord, 2012 26(1): p. 44–9. [PubMed: 21399482]

23. Zhou Y, et al., African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2017 3(1): p. 57–64.

24. Roberts LR, et al., Exploring Experiences and Perceptions of Aging and Cognitive Decline Across Diverse Racial and Ethnic Groups. Gerontol Geriatr Med, 2015 1.

25. Dilworth-Anderson P and Cohen MD, Beyond diversity to inclusion: recruitment and retention of diverse groups in Alzheimer research. Alzheimer Dis Assoc Disord, 2010 24 Suppl: p. S14–18. [PubMed: 22720319]

26. Amorrortu RP, et al., Recruitment of racial and ethnic minorities to clinical trials conducted within specialty clinics: an intervention mapping approach. Trials, 2018 19(1): p. 115. [PubMed: 29454389]

27. George S, Duran N, and Norris K, A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health, 2014 104(2): p. e16–31.

28. Dilworth-Anderson P, et al., Diagnosis and assessment of Alzheimer's disease in diverse populations. Alzheimers Dement, 2008 4(4): p. 305–9. [PubMed: 18631983]

29. Weiner MF, Perspective on race and ethnicity in Alzheimer's disease research. Alzheimers Dement, 2008 4(4): p. 233–8. [PubMed: 18631972]

30. Stern Y, An approach to studying the neural correlates of reserve. Brain Imaging Behav, 2017 11(2): p. 410–416. [PubMed: 27450378]

31. Stern Y, Cognitive reserve. Neuropsychologia, 2009 47(10): p. 2015–28. [PubMed: 19467352]

32. Arenaza-Urquijo EM, Wirth M, and Chetelat G, Cognitive reserve and lifestyle: moving towards preclinical Alzheimer's disease. Front Aging Neurosci, 2015 7: p. 134. [PubMed: 26321944]

33. Chen HY and Panegyres PK, The Role of Ethnicity in Alzheimer's Disease: Findings From The C-PATH Online Data Repository. J Alzheimers Dis, 2016 51(2): p. 515–23. [PubMed: 26890783]

34. de Souza-Talarico JN, et al., Dementia and Cognitive Impairment Prevalence and Associated Factors in Indigenous Populations: A Systematic Review. Alzheimer Dis Assoc Disord, 2016 30(3): p. 281–7. [PubMed: 26840546]

35. Manly JJ, et al., Cognitive decline and literacy among ethnically diverse elders. Journal of Geriatric Psychiatry & Neurology, 2005 18(4): p. 213–7. [PubMed: 16306242]

36. Manly JJ, et al., Literacy and memory decline among ethnically diverse elders. J Clin Exp Neuropsychol, 2003 25(5): p. 680–90. [PubMed: 12815505]

37. Barnes LL, et al., Racial differences in the progression of cognitive decline in Alzheimer disease. Am J Geriatr Psychiatry, 2005 13(11): p. 959–67. [PubMed: 16286439]

38. D, M., Neuropsychological assessment of Hispanic elders: Challenges and psychometric approaches, in Ethnicity and the dementias 2nd ed., G.-T. D Yeo G, Editor. 2006, Routledge: Washington, DC.

39. Black R, et al., Scales as outcome measures for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 5(4): p. 324–339.

40. Parra MA, Overcoming barriers in cognitive assessment of Alzheimer's disease. Dement Neuropsychol, 2014 8(2): p. 95–98. [PubMed: 29213888]

41. Mungas D, et al., Age and education effects on relationships of cognitive test scores with brain structure in demographically diverse older persons. Psychol Aging, 2009 24(1): p. 116–28. [PubMed: 19290743]

42. Leibing A and Cohen L, Thinking about dementia: Culture, loss, and the anthropology of senility 2018: Rutgers University Press.

43. Corriveau RA, et al., Alzheimer's Disease–Related Dementias Summit 2016: National research priorities. Neurology, 2017: p. 10–1212.

44. Rivera MM, B. D, Saez P, Manly J, Increasing culturally competent neuropsychological services for ethnic minority populations: A call to action. Clin Neuropsychol, 2010 24: p. 429–453. [PubMed: 20373222]

45. Parra MA, et al., Dementia in Latin America: Assessing the present and envisioning the future. Neurology, 2018.

46. AR L, Cognitive development: Its cultural and social foundations 1976, Cambridge, MA: Harvard University Press.

47. Dodge HH, et al., Cross-cultural comparisons of the Mini-mental State Examination between Japanese and U.S. cohorts. Int Psychogeriatr, 2009 21(1): p. 113–22. [PubMed: 18925977]

48. Marcopulos B and McLain C, Are our norms "normal"? A 4-year follow-up study of a biracial sample of rural elders with low education. Clinical Neuropsychologist, 2003 17(1): p. 19–33. [PubMed: 12854008]

49. Lucas JA, et al., Mayo's Older African Americans Normative Studies: norms for Boston Naming Test, Controlled Oral Word Association, Category Fluency, Animal Naming, Token Test, Wrat-3 Reading, Trail Making Test, Stroop Test, and Judgment of Line Orientation. Clinical Neuropsychologist, 2005 19(2): p. 243–69. [PubMed: 16019707]

50. O'Bryant SE, et al., Texas Mexican American adult normative studies: Normative data for commonly used clinical neuropsychological measures for English- and Spanish-speakers. Dev Neuropsychol, 2017: p. 1–26.

51. Reiman EM, et al., Clinical impact of updated diagnostic and research criteria for Alzheimer's disease. J Clin Psychiatry, 2011 72(12): p. e37. [PubMed: 22244033]

52. Reiman EM, et al., Alzheimer's disease: implications of the updated diagnostic and research criteria. J Clin Psychiatry, 2011 72(9): p. 1190–6. [PubMed: 21951985]

53. McKhann GM, et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011 7(3): p. 263–9. [PubMed: 21514250]

54. Dubois B, et al., Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. J Alzheimers Dis, 2016 49(3): p. 617–31. [PubMed: 26484931]

55. Dubois B, et al., Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement, 2016 12(3): p. 292–323. [PubMed: 27012484]

56. Weiner MW, et al., The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement, 2017 13(5): p. 561–571. [PubMed: 27931796]

57. ADNI Demographic Report 2012 [cited 2018 January 25, 2018]; Available from: http://adni.loni.usc.edu/wp-content/uploads/2012/08/ADNI_Enroll_Demographics.pdf.

58. Ellis KA, et al., The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 2009 21(4): p. 672–687. [PubMed: 19470201]

59. DeCarli C, et al., Brain behavior relationships among African Americans, whites, and Hispanics. Alzheimer Dis Assoc Disord, 2008 22(4): p. 382–91. [PubMed: 19068502]

60. Aggarwal NT, et al., The association of magnetic resonance imaging measures with cognitive function in a biracial population sample. Arch Neurol, 2010 67(4): p. 475–82. [PubMed: 20385915]

61. Brickman AM, et al., Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol, 2008 65(8): p. 1053–61. [PubMed: 18695055]

62. Knopman DS, et al., Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. Neurology, 2011 76(22): p. 1879–85. [PubMed: 21543737]

63. Liao D, et al., The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. Neuroepidemiology, 1997 16(3): p. 149–62. [PubMed: 9159770]

64. Sencakova D, et al., Hippocampal atrophy correlates with clinical features of Alzheimer disease in African Americans. Arch Neurol, 2001 58(10): p. 1593–7. [PubMed: 11594917]

65. Zahodne LB, Stern Y, and Manly JJ, Differing effects of education on cognitive decline in diverse elders with low versus high educational attainment. Neuropsychology, 2015 29(4): p. 649–57. [PubMed: 25222199]

66. Gu Y, et al., Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population. PLoS One, 2015 10(7): p. e0123743. [PubMed: 26221954]

67. Klunk WE, et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 2004 55(3): p. 306–19. [PubMed: 14991808]

68. Gottesman RF, et al., The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE. Neurology, 2016 87(5): p. 473–80. [PubMed: 27371485]

69. Reiman EM, et al., Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease 2009 p. 6820–6825.

70. Teipel S, et al., Measuring Cortical Connectivity in Alzheimer's Disease as a Brain Neural Network Pathology: Toward Clinical Applications. J Int Neuropsychol Soc, 2016 22(2): p. 138–63. [PubMed: 26888613]

71. Babiloni C, et al., Brain neural synchronization and functional coupling in Alzheimer's disease as revealed by resting state EEG rhythms. Int J Psychophysiol, 2016 103: p. 88–102. [PubMed: 25660305]

72. Amatniek JC, et al., Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia, 2006 47(5): p. 867–72. [PubMed: 16686651]

73. Scarmeas N, et al., Seizures in Alzheimer disease: who, when, and how common? Arch Neurol, 2009 66(8): p. 992–7. [PubMed: 19667221]

74. Purcell SM, et al., Characterizing sleep spindles in 11,630 individuals from the National Sleep Research Resource. Nat Commun, 2017 8: p. 15930. [PubMed: 28649997]

75. Musiek ES, Xiong DD, and Holtzman DM, Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med, 2015 47: p. e148. [PubMed: 25766617]

76. Kryvenko ON, et al., African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance. J Urol, 2016 195(2): p. 301–6. [PubMed: 26341575]

77. Kryvenko ON, Epstein JI, and Cote RJ, Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 (Grade Group 1) Prostate Cancer? J Urol, 2016 196(6): p. 1659–1663. [PubMed: 27343801]

78. Chinea FM, et al., Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification. Oncotarget, 2017 8(13): p. 20802–20812. [PubMed: 28160549]

79. Cavagnolli G, et al., Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis. PLoS One, 2017 12(2): p. e0171315. [PubMed: 28192447]

80. Selvin E, Are There Clinical Implications of Racial Differences in HbA1c? A Difference, to Be a Difference, Must Make a Difference. Diabetes Care, 2016 39(8): p. 1462–7. [PubMed: 27457637]

81. Patton SM, et al., Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults. Fluids Barriers CNS, 2017 14(1): p. 11. [PubMed: 28427421]

82. Rinker JR, 2nd, et al., Higher IgG index found in African Americans versus Caucasians with multiple sclerosis. Neurology, 2007 69(1): p. 68–72. [PubMed: 17606883]

83. Veeranna V, et al., Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: Results from a multi-ethnic cohort. International Journal of Cardiology, 2012.

84. Kant AK and Graubard BI, Race-ethnic, family income, and education differentials in nutritional and lipid biomarkers in US children and adolescents: NHANES 2003–2006. American Journal of Clinical Nutrition, 2012 96(3): p. 601–612. [PubMed: 22836030]

85. Baldwin CM, et al., Differences in Mexican American and non-Hispanic white veterans' homocysteine levels. Journal of Nursing Scholarship, 2007 39(3): p. 235–242. [PubMed: 17760796]

86. Bu L, et al., Polymorphisms in fatty acid binding protein 5 show association with type 2 diabetes. Diabetes Research and Clinical Practice, 2011 92(1): p. 82–91. [PubMed: 21288588]

87. Damcott CM, et al., Variation in the FABP2 promoter alters transcriptional activity and is associated with body composition and plasma lipid levels. Human Genetics, 2003 112(5–6): p. 610–616. [PubMed: 12634920]

88. Choi JC, et al., Diversity of stroke presentation in CADASIL: Study from patients harboring the predominant NOTCH3 mutation R544C. Journal of Stroke and Cerebrovascular Diseases, 2013 22(2): p. 126–131. [PubMed: 21852154]

89. Jun G, N. ACB. GW and et al., MEta-analysis confirms cr1, clu, and picalm as alzheimer disease risk loci and reveals interactions with apoe genotypes. Archives of Neurology, 2010 67(12): p. 1473–1484. [PubMed: 20697030]

90. Bertoli Avella AM, et al., A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease. Neurogenetics, 2002 4(2): p. 97–104. [PubMed: 12484344]

91. Haan MN, et al., Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. Journal of the American Geriatrics Society, 2003 51(2): p. 169–77. [PubMed: 12558712]

92. Simino J, et al., Whole exome sequence-based association analyses of plasma amyloid-beta in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study. PLoS One, 2017 12(7): p. e0180046. [PubMed: 28704393]

93. Ting SK, et al., A novel PSEN1 mutation (I238M) associated with early-onset Alzheimer's disease in an African-American woman. J Alzheimers Dis, 2014 40(2): p. 271–5. [PubMed: 24413619]

94. Athan ES, et al., A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. Jama, 2001 286(18): p. 2257–63. [PubMed: 11710891]

95. Grewal R, et al., Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients. Alzheimers Res Ther, 2016 8(1): p. 43. [PubMed: 27756387]

96. O'Bryant SE, et al., The link between c-reactive protein and alzheimer's disease among mexican americans. Journal of Alzheimer's Disease, 2013 34(3): p. 701–706.

97. O'Bryant SE, et al., A serum protein-based algorithm for the detection of Alzheimer disease. Archives of Neurology, 2010 67(9): p. 1077–1081. [PubMed: 20837851]

98. Miller MA, et al., Ethnic differences in circulating soluble adhesion molecules: the Wandsworth Heart and Stroke Study. Clin Sci (Lond), 2003 104(6): p. 591–8. [PubMed: 12605595]

99. Miller MA and Cappuccio FP, Ethnicity and inflammatory pathways - implications for vascular disease, vascular risk and therapeutic intervention. Curr Med Chem, 2007 14(13): p. 1409–25. [PubMed: 17584053]

100. Hwang SJ, et al., Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation, 1997 96(12): p. 4219–25. [PubMed: 9416885]

101. McDade TW, Hawkley LC, and Cacioppo JT, Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging, and social relations study. Psychosom Med, 2006 68(3): p. 376–81. [PubMed: 16738067]

102. Paalani M, et al., Determinants of inflammatory markers in a bi-ethnic population. Ethn Dis, 2011 21(2): p. 142–9. [PubMed: 21749016]

103. Dinwiddie GY, et al., The Impact of Educational Attainment on Observed Race/Ethnic Disparities in Inflammatory Risk in the 2001–2008 National Health and Nutrition Examination Survey. Int J Environ Res Public Health, 2015 13(1): p. ijerph13010042.

104. Albandar JM, et al., Associations of serum concentrations of IgG, IgA, IgM and interleukin-1beta with early-onset periodontitis classification and race. J Clin Periodontol, 2002 29(5): p. 421–6. [PubMed: 12060424]

105. Mwantembe O, et al., Ethnic differences in allelic associations of the interleukin-1 gene cluster in South African patients with inflammatory bowel disease (IBD) and in control individuals. Immunogenetics, 2001 52(3–4): p. 249–54. [PubMed: 11220627]

106. Elkind MS, et al., Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke, 2002 33(1): p. 31–7. [PubMed: 11779885]

107. Faison WE, et al., Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: Challenges for the future. International Psychogeriatrics, 2007 19(3): p. 539–558. [PubMed: 17451614]

108. Olin JT, et al., Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Dis Assoc Disord, 2002 16 Suppl 2: p. S82–5. [PubMed: 12351920]

109. ROAR, Recruiting Older Adults into Research (ROAR)

110. Mehta KM, et al., Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology, 2005 65(1): p. 159–62. [PubMed: 16009909]

111. Goode RW, et al., African Americans in Standard Behavioral Treatment for Obesity, 2001–2015: What Have We Learned? West J Nurs Res, 2017 39(8): p. 1045–1069. [PubMed: 28322668]

112. Makhoul I, et al., Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients. PLoS One, 2017 12(1): p. e0168550. [PubMed: 28045923]

113. Ganguli M, et al., Who wants a free brain scan? Assessing and correcting for recruitment biases in a population-based sMRI pilot study. Brain Imaging Behav, 2015 9(2): p. 204–12. [PubMed: 24573773]

114. Dodge HH, et al., Characteristics associated with willingness to participate in a randomized controlled behavioral clinical trial using home-based personal computers and a webcam. Trials, 2014 15: p. 508. [PubMed: 25539637]

115. Zhou Y, et al., African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. Alzheimers Dement (N Y), 2017 3(1): p. 57–64. [PubMed: 29067319]

116. Kennedy RE, et al., Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry, 2017 25(10): p. 1150–1159. [PubMed: 28554539]

117. Knopman DS, et al., The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's & Dementia, 2018 14(4): p. 563–575.

118. Olazarán J, et al., Nonpharmacological Therapies in Alzheimer's Disease: A Systematic Review of Efficacy. Dementia and Geriatric Cognitive Disorders, 2010 30(2): p. 161–178. [PubMed: 20838046]

119. Maly RC, et al., Racial/Ethnic Differences in Breast Cancer Outcomes among Older Patients: Effects of Physician Communication and Patient Empowerment. Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2008 27(6): p. 728–736.

120. Wong GH, et al., Development of Six Arts, a Culturally Appropriate Multimodal Nonpharmacological Intervention in Dementia. Gerontologist, 2015 55(5): p. 865–74. [PubMed: 25378464]

121. Graham-Phillips A, et al., Differences by Race/Ethnicity in the Delivery of the Resources for Enhancing Alzheimer's Caregiver Health (REACH II) Dementia Caregiver Intervention. Journal of the American Geriatrics Society, 2016 64(8): p. 1662–1667. [PubMed: 27294873]

122. Gavin JR, Fox KM, and Grandy S, Race/Ethnicity and gender differences in health intentions and behaviors regarding exercise and diet for adults with type 2 diabetes: A cross-sectional analysis. BMC Public Health, 2011 11(1): p. 533. [PubMed: 21729303]

123. Dean LT, et al., Great expectations: racial differences in outcome expectations for a weight lifting intervention among black and white breast cancer survivors with or without lymphedema. Psychooncology, 2016 25(9): p. 1064–70. [PubMed: 27192633]

124. Jessen F, et al., A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement, 2014 10(6): p. 844–52. [PubMed: 24798886]

125. Barnes L, et al., Memory complaints are related to Alzheimer disease pathology in older persons. Neurology, 2006 67(9): p. 1581–1585. [PubMed: 17101887]

126. Mendes T, et al., Memory complaints in healthy young and elderly adults: reliability of memory reporting. Aging Ment Health, 2008 12(2): p. 177–82. [PubMed: 18389397]

127. Bazargan M and Barbre AR, The effects of depression, health status, and stressful life-events on self-reported memory problems among aged blacks. The International Journal of Aging and Human Development, 1994 38(4): p. 351–362. [PubMed: 7960182]

128. Ficker LJ, et al., Perceived cognitive impairment among African American elders: Health and functional impairments in daily life. Aging & mental health, 2014 18(4): p. 471–480. [PubMed: 24328435]

129. Blazer DG, et al., Memory complaint as a predictor of cognitive decline: a comparison of African American and White elders. Journal of Aging and Health, 1997 9(2): p. 171–184. [PubMed: 10182402]

130. Sims RC, et al., Subjective memory in older African Americans. Exp Aging Res, 2011 37(2): p. 220–40. [PubMed: 21424958]

131. Sperling SA, et al., Subjective Memory Change, Mood, and Cerebrovascular Risk Factors in Older African Americans. J Geriatr Psychiatry Neurol, 2017 30(6): p. 324–330. [PubMed: 28954594]

132. Harwood D, et al., Memory complaints in the elderly: A comparative analysis of informant and subject reports among Hispanics and White non-Hispanics. Clinical Gerontologist: The Journal of Aging and Mental Health 18(3): p. 56–60.

133. Hall JR, W. A, Johnson LA, Edwards M, O'Bryant SE, Characteristics of cognitively normal Mexican-Americans with cognitive complaints. Journal of Alzheimer's Disease, 2018 61(4): p. 1485–92.

134. Laditka JN, et al., Older adults' concerns about cognitive health: commonalities and differences among six United States ethnic groups. Ageing & Society, 2011 31(7): p. 1202–1228.

135. Lyketsos CG, Neuropsychiatric Symptoms in Dementia: Overview and Measurement Challenges. J Prev Alzheimers Dis, 2015 2(3): p. 155–156. [PubMed: 26779454]

136. Apostolova LG, et al., Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dement Geriatr Cogn Disord, 2014 37(5–6): p. 315–26. [PubMed: 24481207]

137. Bassiony MM, et al., Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates. Int J Geriatr Psychiatry, 2000 15(2): p. 99–107. [PubMed: 10679840]

138. Sink KM, et al., Ethnic differences in the prevalence and pattern of dementia-related behaviors. Journal of the American Geriatrics Society, 2004 52(8): p. 1277–83. [PubMed: 15271114]

139. Nagata T, et al., Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study. Int J Geriatr Psychiatry, 2017 32(12): p. 1264–1271. [PubMed: 27714849]

140. Salazar R, Dwivedi AK, and Royall DR, Cross-Ethnic Differences in the Severity of Neuropsychiatric Symptoms in Persons With Mild Cognitive Impairment and Alzheimer's Disease. J Neuropsychiatry Clin Neurosci, 2017 29(1): p. 13–21. [PubMed: 27417070]

141. Salazar R, Royall DR, and Palmer RF, Neuropsychiatric symptoms in community-dwelling Mexican-Americans: results from the Hispanic Established Population for Epidemiological Study of the Elderly (HEPESE) study. Int J Geriatr Psychiatry, 2015 30(3): p. 300–7. [PubMed: 24838594]

142. Lee SE and Casado BL, Assessment of Alzheimer's disease symptom recognition in Korean Americans and psychometric analysis of Alzheimer's Disease Symptom Recognition Scale (ADSRS). J Gerontol Soc Work, 2015 58(3): p. 289–305. [PubMed: 25602359]

143. Hinton L, Chambers D, and Velasquez A, Making sense of behavioral disturbances in persons with dementia: Latino family caregiver attributions of neuropsychiatric inventory domains. Alzheimer Dis Assoc Disord, 2009 23(4): p. 401–5. [PubMed: 19568150]

144. Wells BA, G. R, Bernabe D, Kazmer MM, Schettini G, Springer J, Sharma D, Meng H, Graff-Radford N, African American Dementia Caregiver Problem Inventory: Descriptive analysis and initial psychometric evaluation. Rehabilitation Psychology, 2017 61(1): p. 25–35.

145. Toth-Cohen S, Factors influencing appraisal of upset in black caregivers of persons with Alzheimer disease and related dementias. Alzheimer Dis Assoc Disord, 2004 18(4): p. 247–55. [PubMed: 15592139]

146. Graham-Phillips A, et al., Racial and Ethnic Differences in the Delivery of the Resources for Enhancing Alzheimer's Caregiver Health II Intervention. J Am Geriatr Soc, 2016 64(8): p. 1662–7. [PubMed: 27294873]

147. Sorkin DH, Pham E, and Ngo-Metzger Q, Racial and ethnic differences in the mental health needs and access to care of older adults in california. J Am Geriatr Soc, 2009 57(12): p. 2311–7. [PubMed: 19943830]

148. Miller EA, Schneider LS, and Rosenheck RA, Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. Int Psychogeriatr, 2011 23(1): p. 44–53. [PubMed: 20214847]

149. Rattinger GB, et al., Clinic visits and prescribing patterns among Veterans Affairs Maryland Health Care System dementia patients. J Nutr Health Aging, 2010 14(8): p. 677–83. [PubMed: 20922345]

150. Hernandez S, et al., Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables. J Alzheimers Dis, 2010 19(2): p. 665–72. [PubMed: 20110610]

151. Thorpe CT, et al., Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries. J Am Geriatr Soc, 2016 64(9): p. 1806–14. [PubMed: 27549029]

152. Xiong GL, et al., Antipsychotic Use in a Diverse Population With Dementia: A Retrospective Review of the National Alzheimer's Coordinating Center Database. J Neuropsychiatry Clin Neurosci, 2015 27(4): p. 326–32. [PubMed: 26488486]

153. Gonyea JG, Lopez LM, and Velasquez EH, The Effectiveness of a Culturally Sensitive Cognitive Behavioral Group Intervention for Latino Alzheimer's Caregivers. Gerontologist, 2016 56(2): p. 292–302. [PubMed: 24855313]

154. Henderson JN, Cultural Construction of Dementia Progression, Behavioral Aberrations, and Situational Ethnicity: An Orthogonal Approach. Care Manag J, 2015 16(2): p. 95–105. [PubMed: 26171509]

155. McKhann GM, et al., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association, 2011 7(3): p. 263–269.

156. Dubois B, et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology, 2014 13(6): p. 614–29. [PubMed: 24849862]

157. Hyman BT, et al., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2012 8(1): p. 1–13.

158. Murray ME, et al., Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. The Lancet. Neurology, 2011 10(9): p. 785–96. [PubMed: 21802369]

159. Ossenkoppele R, et al., Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain, 2016 139(Pt 5): p. 1551–67. [PubMed: 26962052]

160. van der Flier WM, et al., Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol, 2011 10(3): p. 280–8. [PubMed: 21185234]

161. Dickerson BC, Wolk DA, and A.s.D.N. Initiative, Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. Journal of Neurology, Neurosurgery & Psychiatry, 2011 82(1): p. 45–51.

162. Murray ME, et al., Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. The Lancet Neurology, 2011 10(9): p. 785–796. [PubMed: 21802369]

163. Wolk DA, et al., Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer's disease. Proceedings of the National Academy of Sciences, 2010 107(22): p. 10256–10261.

164. Barnes J, et al., Alzheimer's disease first symptoms are age dependent: evidence from the NACC dataset. Alzheimer's & dementia: the journal of the Alzheimer's Association, 2015 11(11): p. 1349–1357.

165. Katz MJ, et al., Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord, 2012 26(4): p. 335–43. [PubMed: 22156756]

166. Petersen RC, et al., Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology, 2010 75(10): p. 889–97. [PubMed: 20820000]

167. Lee LK, et al., Prevalence of gender disparities and predictors affecting the occurrence of mild cognitive impairment (MCI). Arch Gerontol Geriatr, 2012 54(1): p. 185–91. [PubMed: 21546098]

168. Koedam EL, et al., Early-versus late-onset Alzheimer's disease: more than age alone. Journal of Alzheimer's Disease, 2010 19(4): p. 1401–1408.

169. Balasa M, et al., Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology, 2011 76(20): p. 1720–1725. [PubMed: 21576687]

170. van der Flier WM, et al., Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ε4 allele. The Lancet Neurology, 2011 10(3): p. 280–288. [PubMed: 21185234]

171. Warren JD, Fletcher PD, and Golden HL, The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol, 2012 8(8): p. 451–64. [PubMed: 22801974]

172. Dickerson BC, et al., Approach to atypical Alzheimer's disease and case studies of the major subtypes. CNS spectrums, 2017 22(6): p. 439–449. [PubMed: 28196556]

173. Gamaldo AA, et al., Assessing mild cognitive impairment among older African Americans. Int J Geriatr Psychiatry, 2010 25(7): p. 748–55. [PubMed: 20069588]

174. Manly JJ, et al., Frequency and Course of Mild Cognitive Impairment in a Multiethnic Community. Annals of neurology, 2008 63(4): p. 494–506. [PubMed: 18300306]

175. He J, et al., Differences of Brain volume, Hippocampal volume, Cerebrovascular risk factors and APOE4 among MCI subtypes. Archives of neurology, 2009 66(11): p. 1393–1399. [PubMed: 19901172]

176. Cushman M, et al., Estimated 10-year stroke risk by region and race in the United States: geographic and racial differences in stroke risk. Ann Neurol, 2008 64(5): p. 507–13. [PubMed: 19067365]

177. Reitz C, et al., Hypertension and the risk of mild cognitive impairment. Arch Neurol, 2007 64(12): p. 1734–40. [PubMed: 18071036]

178. Roberts RO, et al., Coronary heart disease is associated with non-amnestic mild cognitive impairment. Neurobiol Aging, 2010 31(11): p. 1894–902. [PubMed: 19091445]

179. Pedraza OL, et al., Mild cognitive impairment (MCI) and dementia in a sample of adults in the city of Bogota. Dement Neuropsychol, 2017 11(3): p. 262–269. [PubMed: 29213523]

180. Mez J, et al., Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors. Alzheimer Dis Assoc Disord, 2013 27(3): p. 218–25. [PubMed: 23954887]

181. Goodman RA, et al., Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimers Dement, 2017 13(1): p. 28–37. [PubMed: 27172148]

182. Fitten LJ, Ortiz F, and Ponton M, Frequency of Alzheimer's disease and other dementias in a community outreach sample of Hispanics. J Am Geriatr Soc, 2001 49(10): p. 1301–8. [PubMed: 11890488]

183. Rippon GA, et al., Presenilin 1 mutation in an african american family presenting with atypical alzheimer dementia. Archives of Neurology, 2003 60(6): p. 884–888. [PubMed: 12810495]

184. Brouwers N, Sleegers K, and Van Broeckhoven C, Molecular genetics of Alzheimer's disease: an update. Ann Med, 2008 40(8): p. 562–83. [PubMed: 18608129]

185. Bernardi L, et al., The effects of APOE and tau gene variability on risk of frontotemporal dementia. Neurobiol Aging, 2006 27(5): p. 702–9. [PubMed: 15904995]

186. Youn YC, et al., Probable novel PSEN2 Val214Leu mutation in Alzheimer's disease supported by structural prediction. BMC Neurol, 2014 14: p. 105. [PubMed: 24885952]

187. Bai Y, et al., Association of Mutations of Presenilin-2 Gene and Sporadic Alzheimer's Disease. Journal of China Medical University, 2011 40(4): p. 357–359.

188. Zatti G, et al., The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca2+ release from intracellular stores. Neurobiol Dis, 2004 15(2): p. 269–78. [PubMed: 15006697]

189. Zatti G, et al., Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium, 2006 39(6): p. 539–50. [PubMed: 16620965]

190. Walker ES, et al., Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem, 2005 92(2): p. 294–301. [PubMed: 15663477]

191. Li D, et al., Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am J Hum Genet, 2006 79(6): p. 1030–9. [PubMed: 17186461]

192. Chen JA, et al., A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy. JAMA neurology, 2015 72(4): p. 414–422. [PubMed: 25706306]

193. Ringman JM, et al., Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. Journal of Neuropathology and Experimental Neurology, 2016 75(3): p. 284–290. [PubMed: 26888304]

194. Ighodaro ET, et al., Challenges and Considerations Related to Studying Dementia in Blacks/ African Americans. Journal of Alzheimer's Disease, 2017 60(1): p. 1–10.

195. Lott IT and Dierssen M, Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol, 2010 9(6): p. 623–33. [PubMed: 20494326]

196. McCarron M, et al., A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res, 2017 61(9): p. 843–852. [PubMed: 28664561]

197. Dubois B, et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol, 2014 13(6): p. 614–29. [PubMed: 24849862]

198. Strydom A, et al., Prevalence of dementia in intellectual disability using different diagnostic criteria. Br J Psychiatry, 2007 191: p. 150–7. [PubMed: 17666500]

199. Sheehan R, et al., Dementia diagnostic criteria in Down syndrome. Int J Geriatr Psychiatry, 2015 30(8): p. 857–63. [PubMed: 25363568]

200. Zis P and Strydom A, Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free Radic Biol Med, 2018 114: p. 3–9. [PubMed: 28870521]

201. Miodrag N, et al., Deaths among children, adolescents, and young adults with Down syndrome. J Appl Res Intellect Disabil, 2013 26(3): p. 207–14. [PubMed: 23580207]

202. Chaput JL, Adults with Down syndrome and Alzheimer's disease: Comparison of services received in group homes and in special care units. Gerontological Social Work, 2002 38(1/2): p. 197–211.

203. Janicki MP, et al., Group home care for adults with intellectual disabilities and Alzheimer's disease. Dementia, 2005 4: p. 361–385.

204. Innes A, Morgan D, and Kosteniuk J, Dementia care in rural and remote settings: a systematic review of informal/family caregiving. Maturitas, 2011 68(1): p. 34–46. [PubMed: 21093996]

205. Bedard M, Koivuranta A, and Stuckey A, Health impact on caregivers of providing informal care to a cognitively impaired older adult: rural versus urban settings. Can J Rural Med, 2004 9(1): p. 15–23. [PubMed: 15603671]

206. Montoro-Rodriguez J, Kosloski K, and Montgomery RJ, Evaluating a practice-oriented service model to increase the use of respite services among minorities and rural caregivers. Gerontologist, 2003 43(6): p. 916–24. [PubMed: 14704392]

207. Heller T, et al., Adaptation of Hispanic families to a member with mental retardation. Am J Ment Retard, 1994 99(3): p. 289–300. [PubMed: 7865204]

208. Magana S and Smith MJ, Health outcomes of midlife and older Latina and black American mothers of children with developmental disabilities. Ment Retard, 2006 44(3): p. 224–34. [PubMed: 16677067]

209. Braddock D, et al., Living circumstances of children and adults with mental retardation or developmental disabilities in the United States, Canada, England and Wales, and Australia. Ment Retard Dev Disabil Res Rev, 2001 7(2): p. 115–21. [PubMed: 11389566]

210. Blacher J, et al., Depression in Latina mothers of children with mental retardation: a neglected concern. Am J Ment Retard, 1997 101(5): p. 483–96. [PubMed: 9083605]

211. Magana S, Seltzer MM, and Krauss MW, Cultural context of caregiving: differences in depression between Puerto Rican and non-Latina White mothers of adults with mental retardation. Ment Retard, 2004 42(1): p. 1–11. [PubMed: 14720097]

212. Organization, W.H., Top Ten Causes of Death 2017.

213. UNAIDS report for 2003: most deaths and new infections ever; some good news. AIDS Treat News, 2003(396): p. 3.

214. Fiscella K and Williams DR, Health disparities based on socioeconomic inequities: implications for urban health care. Academic Medicine, 2004 79(12): p. 1139–1147. [PubMed: 15563647]

215. O'Brien KK, et al., Putting episodic disability into context: a qualitative study exploring factors that influence disability experienced by adults living with HIV/AIDS. J Int AIDS Soc, 2009 12: p. 5.

216. Ludwig J, et al., Neighborhoods, obesity, and diabetes--a randomized social experiment. N Engl J Med, 2011 365(16): p. 1509–19. [PubMed: 22010917]

217. McEwen BS and Stellar E, Stress and the individual. Mechanisms leading to disease. Arch Intern Med, 1993 153(18): p. 2093–101. [PubMed: 8379800]

218. Sinha R and Jastreboff AM, Stress as a common risk factor for obesity and addiction. Biol Psychiatry, 2013 73(9): p. 827–35. [PubMed: 23541000]

219. McEwen BS and Wingfield JC, What is in a name? Integrating homeostasis, allostasis and stress. Horm Behav, 2010 57(2): p. 105–11. [PubMed: 19786032]

220. Brickman AM, Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep, 2013 13(12): p. 415. [PubMed: 24190781]

221. Brickman AM, et al., Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol, 2012 69(12): p. 1621–7. [PubMed: 22945686]

222. Brickman AM, et al., Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging, 2015 36(1): p. 27–32. [PubMed: 25155654]

223. Brickman AM, et al., Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol, 2008 65(9): p. 1202–8. [PubMed: 18779424]

224. Lee S, et al., White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol, 2016 79(6): p. 929–39. [PubMed: 27016429]

225. Zahodne LB, et al., Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites. Curr Alzheimer Res, 2015 12(7): p. 632–9. [PubMed: 26027808]

226. Meier IB, et al., White matter predictors of cognitive functioning in older adults. J Int Neuropsychol Soc, 2012 18(3): p. 414–27. [PubMed: 22390883]

227. Oh ES, et al., Delirium in Older Persons: Advances in Diagnosis and Treatment. Jama, 2017 318(12): p. 1161–1174. [PubMed: 28973626]

228. Campbell NL, et al., Race and documentation of cognitive impairment in hospitalized older adults. J Am Geriatr Soc, 2014 62(3): p. 506–11. [PubMed: 24576177]

229. Kales HC, et al., Recorded delirium in a national sample of elderly inpatients: potential implications for recognition. J Geriatr Psychiatry Neurol, 2003 16(1): p. 32–8. [PubMed: 12641371]

230. Kales HC, et al., Race and inpatient psychiatric diagnoses among elderly veterans. Psychiatr Serv, 2000 51(6): p. 795–800. [PubMed: 10828113]

231. Tang S, et al., The psychogeriatric patient in the emergency room: focus on management and disposition. ISRN Psychiatry, 2014 2014: p. 413572. [PubMed: 24734206]

232. DoEaSA, U.N.P.D., World population ageing reports 2015.

233. Evered L, et al., Postoperative cognitive dysfunction is independent of type of surgery and anesthetic. Anesth Analg, 2011 112(5): p. 1179–85. [PubMed: 21474666]

234. Moller JT, et al., Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet, 1998 351(9106): p. 857–61. [PubMed: 9525362]

235. Xu T, et al., Risk factors for early postoperative cognitive dysfunction after non-coronary bypass surgery in Chinese population. J Cardiothorac Surg, 2013 8: p. 204. [PubMed: 24175992]

236. Evered LA, et al., Prevalence of Dementia 7.5 Years after Coronary Artery Bypass Graft Surgery. Anesthesiology, 2016 125(1): p. 62–71. [PubMed: 27127919]

237. Siega-Riz AM, et al., Food-group and nutrient-density intakes by Hispanic and Latino backgrounds in the Hispanic Community Health Study/Study of Latinos. Am J Clin Nutr, 2014 99(6): p. 1487–98. [PubMed: 24760972]

238. Lin H, Bermudez OI, and Tucker KL, Dietary patterns of Hispanic elders are associated with acculturation and obesity. J Nutr, 2003 133(11): p. 3651–7. [PubMed: 14608089]

239. Hiza HA, et al., Diet quality of Americans differs by age, sex, race/ethnicity, income, and education level. J Acad Nutr Diet, 2013 113(2): p. 297–306. [PubMed: 23168270]

240. Satia JA, Diet-related disparities: understanding the problem and accelerating solutions. J Am Diet Assoc, 2009 109(4): p. 610–5. [PubMed: 19328255]

241. Salihu HM, et al., Community-based fortified dietary intervention improved health outcomes among low-income African-American women. Nutr Res, 2016 36(8): p. 771–9. [PubMed: 27440531]

242. Aksan N, et al., Naturalistic distraction and driving safety in older drivers. Hum 10 Factors, 2013 55(4): p. 841–53.

243. Casagrande SS, et al., Have Americans increased their fruit and vegetable intake? The trends between 1988 and 2002. Am J Prev Med, 2007 32(4): p. 257–63. [PubMed: 17383556]

244. D'Alessandro C, Piccoli GB, and Cupisti A, The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol, 2015 16: p. 9. [PubMed: 25603926]

245. Torres SJ, et al., Dietary patterns are associated with cognition among older people with mild cognitive impairment. Nutrients, 2012 4(11): p. 1542–51. [PubMed: 23201831]

246. Morris MC, et al., MIND diet slows cognitive decline with aging. Alzheimers Dement, 2015 11(9): p. 1015–22. [PubMed: 26086182]

247. Alzheimer's Disease International, Nutrition and dementia: A review of available research 2014.

248. Franx BAA, et al., Weight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy. Drugs Aging, 2017 34(6): p. 425–436. [PubMed: 28478593]

249. Fielding RA, et al., The paradox of overnutrition in aging and cognition. Ann N Y Acad Sci, 2013 1287: p. 31–43. [PubMed: 23682739]

250. Gustafson DR, et al., New Perspectives on Alzheimer's Disease and Nutrition. J Alzheimers Dis, 2015 46(4): p. 1111–27. [PubMed: 26402637]

251. Morris MC and Tangney CC, A potential design flaw of randomized trials of vitamin supplements. JAMA, 2011 305(13): p. 1348–9. [PubMed: 21467288]

252. Gu Y, et al., Mediterranean diet and brain structure in a multiethnic elderly cohort. Neurology, 2015 85(20): p. 1744–51. [PubMed: 26491085]

253. Gu Y, et al., Alcohol intake and brain structure in a multiethnic elderly cohort. Clin Nutr, 2014 33(4): p. 662–7. [PubMed: 24011900]

254. Gu Y, et al., Nutrient intake and plasma beta-amyloid. Neurology, 2012 78(23): p. 1832–40. [PubMed: 22551728]

255. Morris MC, et al., Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. J Alzheimers Dis, 2006 9(4): p. 435–43. [PubMed: 16917153]

256. Tangney CC, et al., Vitamin B12, cognition, and brain MRI measures: a cross-sectional examination. Neurology, 2011 77(13): p. 1276–82. [PubMed: 21947532]

257. Tangney CC, et al., Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. Neurology, 2009 72(4): p. 361–7. [PubMed: 19171834]

258. Miller JW, et al., Vitamin D Status and Rates of Cognitive Decline in a Multiethnic Cohort of Older Adults. JAMA Neurol, 2015 72(11): p. 1295–303. [PubMed: 26366714]

259. Morris MC, et al., MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement, 2015 11(9): p. 1007–14. [PubMed: 25681666]

260. Gu Y, et al., Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease. J Alzheimers Dis, 2010 22(2): p. 483–92. [PubMed: 20847399]

261. Beydoun MA, et al., n-3 Fatty acids, hypertension and risk of cognitive decline among older adults in the Atherosclerosis Risk in Communities (ARIC) study. Public Health Nutr, 2008 11(1): p. 17–29. [PubMed: 17625029]

262. Gu Y, et al., White matter integrity as a mediator in the relationship between dietary nutrients and cognition in the elderly. Ann Neurol, 2016 79(6): p. 1014–25. [PubMed: 27129740]

263. Wright RS, et al., Diet quality and cognitive function in an urban sample: findings from the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study. Public Health Nutr, 2017 20(1): p. 92–101. [PubMed: 27256509]

264. Beydoun MA, et al., Dietary antioxidant intake and its association with cognitive function in an ethnically diverse sample of US adults. Psychosom Med, 2015 77(1): p. 68–82. [PubMed: 25478706]

265. Koyama A, et al., Association between the Mediterranean diet and cognitive decline in a biracial population. J Gerontol A Biol Sci Med Sci, 2015 70(3): p. 354–9. [PubMed: 24994847]

266. Almiron-Roig E, et al., Dietary assessment in minority ethnic groups: a systematic review of instruments for portion-size estimation in the United Kingdom. Nutr Rev, 2017 75(3): p. 188–213. [PubMed: 28340101]

267. Ritchie K, A. M, Huppert FA, Nargeot C, Pinek B, Ledesert B, Computerized cognitive examination of the elderly (ECO): the development of a neuropsychological examination for clinic and poulation use. International Journal of Geriatric Psychiatry, 1993 8(11): p. 899–914.

268. Manera V, et al., 'Kitchen and cooking,' a serious game for mild cognitive impairment and Alzheimer's disease: a pilot study. Front Aging Neurosci, 2015 7: p. 24. [PubMed: 25852542]

269. Alm N, A. A, Ellis M, Dye R, Gowans G, Campbell JA, A cognitive prosthesis and communication support for people with dementia. Neuropsychological Rehabilitation, 2004 14(1): p. 117–134.

270. Meiland FJ, B. A, Savenstedt S, Bentvelzen S, Davies RJ, Mulvenna MD et al. Usability of a new electronic assistive device for community-dwelling persons with mild dementia. Aging Mental Health, 2012 16(5): p. 584–91. [PubMed: 22360649]

271. Akl A, C. B, Mattek N, Kaye J, Austin D, Mihailidis A, Clusterin home activity distributions for automatic detection of mild cognitive impairment in older adults. Journal of Ambient Intellengence and Smart Environments, 2016 8(4): p. 437–51.

272. Inoue K, S. N, Okada M, Sasaki C, Nakamura M, Wada K, Effective application of PALRO: A humanoid type robot for people with dementia. ICCHP 2014: Computers helping people with special needs, 2014: p. 451–54.

273. Kim H, Understanding Internet Use Among Dementia Caregivers: Results of Secondary Data Analysis Using the US Caregiver Survey Data. Interact J Med Res, 2015 4(1): p. e1. [PubMed: 25707033]

274. Joddrell P and Astell AJ, Studies Involving People With Dementia and Touchscreen Technology: A Literature Review. JMIR Rehabil Assist Technol, 2016 3(2): p. e10. [PubMed: 28582254]

275. Romero HR, et al., Challenges in the neuropsychological assessment of ethnic minorities: summit proceedings. Clin Neuropsychol, 2009 23(5): p. 761–79. [PubMed: 19530035]

276. Vasquez E, et al., Racial/Ethnic Differences in Trajectories of Cognitive Function in Older Adults. J Aging Health, 2016 28(8): p. 1382–1402. [PubMed: 26719488]

277. Reed M, K. S, Yeager P The community research for assistive technology survey 2005 [cited 2018 January 19]; Available from: https://abilitytools.org/about/docs/ATRaceDataFINAL.pdf. .

278. Tshiswaka DI, L. C, Chiu C-Y, Alston R, Lewis A, Assistive technology use by disability type and race: Exploration of a population-based health survey. Assistive Technology, 2016 11(2): p. 124–32.

279. Kramer B, et al., Technology in dementia care: A cross-cultural study of acceptance. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 11(7): p. P236.

280. Jones L, Jacklin K, and O'Connell ME, Development and Use of Health-Related Technologies in Indigenous Communities: Critical Review. J Med Internet Res, 2017 19(7): p. e256. [PubMed: 28729237]

281. Lee JA, et al., Usages of Computers and Smartphones to Develop Dementia Care Education Program for Asian American Family Caregivers. Healthc Inform Res, 2017 23(4): p. 338–342. [PubMed: 29181245]

282. An N, C. H, Shahir JY, Levkoff S, A self-directed learning (SDL) sysetm for Chinese dementia caregivers. . Innovation in Aging, 2017 1(1): p. 42.

283. Zheng X and Woo BK, E-mental health in ethnic minority: A comparison of youtube and talk-based educational workshops in dementia. Asian J Psychiatr, 2017 25: p. 246–248. [PubMed: 28262161]

284. Xiong C, A. A, Colantonio A, Mihailidis A, Sixsmith A, Liu L, Needs and preferences of technology among Chinese family caregivers of persons with dementia: A sex and gender perspective. Innovation in Aging, 2017 1(1): p. 14.